<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Res Ther</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Res Ther</journal-id><journal-title-group><journal-title>Alzheimer's Research &#x00026; Therapy</journal-title></journal-title-group><issn pub-type="epub">1758-9193</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25580161</article-id><article-id pub-id-type="pmc">4288216</article-id><article-id pub-id-type="publisher-id">s13195-014-0073-2</article-id><article-id pub-id-type="doi">10.1186/s13195-014-0073-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Alpha-synuclein biology in Lewy body diseases</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Kim</surname><given-names>Woojin Scott</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>w.kim@unsw.edu.au</email></contrib><contrib contrib-type="author" id="A2"><name><surname>K&#x000e5;gedal</surname><given-names>Katarina</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>katarina.kagedal@liu.se</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Halliday</surname><given-names>Glenda M</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>g.halliday@neura.edu.au</email></contrib></contrib-group><aff id="I1"><label>1</label>Neuroscience Research Australia, Barker Street, Randwick 2031, NSW, Australia</aff><aff id="I2"><label>2</label>School of Medical Sciences, University of New South Wales, Sydney 2052, NSW,
Australia</aff><aff id="I3"><label>3</label>Department of Clinical and Experimental Medicine, Link&#x000f6;ping University,
Link&#x000f6;ping, SE-581 85, Sweden</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>27</day><month>10</month><year>2014</year></pub-date><volume>6</volume><issue>5</issue><fpage>73</fpage><lpage>73</lpage><permissions><copyright-statement>Copyright &#x000a9; 2014 Kim et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Kim et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>The licensee has exclusive rights to distribute this article, in any medium, for 12
months following its publication. After this time, the article is available under the
terms of the Creative Commons Attribution License
(<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted
use, distribution, and reproduction in any medium, provided the original work is
properly credited. The Creative Commons Public Domain Dedication waiver
(<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data
made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://alzres.com/content/6/5/73"/><abstract><p>&#x003b1;-Synuclein is an abundantly expressed neuronal protein that is at the center of
focus in understanding a group of neurodegenerative disorders called
&#x003b1;-synucleinopathies, which are characterized by the presence of aggregated
&#x003b1;-synuclein intracellularly. Primary &#x003b1;-synucleinopathies include
Parkinson&#x02019;s disease (PD), dementia with Lewy bodies and multiple system
atrophy, with &#x003b1;-synuclein also found secondarily in a number of other diseases,
including Alzheimer&#x02019;s disease. Understanding how &#x003b1;-synuclein aggregates
form in these different disorders is important for the understanding of its
pathogenesis in Lewy body diseases. PD is the most prevalent of the
&#x003b1;-synucleinopathies and much of the initial research on &#x003b1;-synuclein Lewy
body pathology was based on PD but is also relevant to Lewy bodies in other diseases
(dementia with Lewy bodies and Alzheimer&#x02019;s disease). Polymorphism and mutation
studies of <italic>SNCA</italic>, the gene that encodes &#x003b1;-synuclein, provide much
evidence for a causal link between &#x003b1;-synuclein and PD. Among the primary
&#x003b1;-synucleinopathies, multiple system atrophy is unique in that &#x003b1;-synuclein
deposition occurs in oligodendrocytes rather than neurons. It is unclear whether
&#x003b1;-synuclein originates from oligodendrocytes or whether it is transmitted
somehow from neurons. &#x003b1;-Synuclein exists as a natively unfolded monomer in the
cytosol, but in the presence of lipid membranes it is thought to undergo a
conformational change to a folded &#x003b1;-helical secondary structure that is prone to
forming dimers and oligomers. Posttranslational modification of &#x003b1;-synuclein,
such as phosphorylation, ubiquitination and nitration, has been widely implicated in
&#x003b1;-synuclein aggregation process and neurotoxicity. Recent studies using animal
and cell models, as well as autopsy studies of patients with neuron transplants,
provided compelling evidence for prion-like propagation of &#x003b1;-synuclein. This
observation has implications for therapeutic strategies, and much recent effort is
focused on developing antibodies that target extracellular &#x003b1;-synuclein.</p></abstract></article-meta></front><body><sec><title>1 Introduction</title><p>&#x003b1;-Synuclein is a 140 amino acid, natively unfolded protein predominantly localized
in the presynaptic terminals of neurons. In the past two decades &#x003b1;-synuclein has
been the center of focus in understanding the etiology of a group of overlapping
neurodegenerative disorders called &#x003b1;-synucleinopathies, which includes
Parkinson&#x02019;s disease (PD), Parkinson&#x02019;s disease dementia (PDD), dementia with
Lewy bodies (DLB), multiple system atrophy (MSA) and a number of less-well characterized
neuroaxonal dystrophies. &#x003b1;-Synuclein is encoded by the <italic>SNCA</italic> gene on 4q21,
and was first identified as the nonamyloid component of &#x003b2;-amyloid plaques in the
brain of patients with Alzheimer&#x02019;s disease (AD) [<xref ref-type="bibr" rid="B1">1</xref>]. Although AD is pathologically quite distinct from
&#x003b1;-synucleinopathies, &#x003b1;-synuclein aggregates have been found in the majority of
AD brains, mostly restricted to the amygdala [<xref ref-type="bibr" rid="B2">2</xref>],[<xref ref-type="bibr" rid="B3">3</xref>]. Despite much
research into &#x003b1;-synuclein biology, the exact function of &#x003b1;-synuclein is still
elusive. &#x003b1;-Synuclein is thought to play a role in maintaining a supply of synaptic
vesicles in presynaptic terminals. The protein has also been suggested to be involved in
regulating the release of the neurotransmitter dopamine in controlling voluntary and
involuntary movements.</p><p>The universal feature of &#x003b1;-synucleinopathies is the presence of proteinaceous
intracellular entities or bodies containing aggregates of &#x003b1;-synuclein. These bodies
differ somewhat in appearance in different &#x003b1;-synucleinopathies, and are called Lewy
bodies in PD and DLB [<xref ref-type="bibr" rid="B4">4</xref>], glial cytoplasmic
inclusions in MSA [<xref ref-type="bibr" rid="B5">5</xref>] and axonal spheroids in
neuroaxonal dystrophies [<xref ref-type="bibr" rid="B6">6</xref>]. Much evidence
indicates that the mechanism underpinning &#x003b1;-synucleinopathies is the misfolding of
&#x003b1;-synuclein into aggregates [<xref ref-type="bibr" rid="B4">4</xref>]. <italic>In
vitro</italic> studies have shown that &#x003b1;-synuclein aggregates (that is, oligomers)
cause a series of secondary processes leading to neuroinflammation, neurodegeneration
and cell death [<xref ref-type="bibr" rid="B7">7</xref>]. Apart from the pathogenic
dogma of neurotoxicity of aggregated &#x003b1;-synuclein, loss of &#x003b1;-synuclein monomers
(that is, loss of function) from their physiological location may also contribute to
neurodegeneration [<xref ref-type="bibr" rid="B8">8</xref>]. A radical idea of
prion-like propagation has been proposed for &#x003b1;-synuclein transmission between
cells. New developments in &#x003b1;-synuclein transmission highlight the importance of
extracellular &#x003b1;-synuclein in therapeutic strategies. In this review we will discuss
&#x003b1;-synuclein biology, &#x003b1;-synucleinopathies and recent developments in
&#x003b1;-synuclein disease mechanisms and therapies.</p></sec><sec><title>2 &#x003b1;-Synuclein biology</title><p>&#x003b1;-Synuclein is abundantly expressed in the human brain, making up as much as 1% of
protein content in the cytosol. This protein is expressed throughout the brain, with
high levels in the neocortex, hippocampus, substantia nigra, thalamus and cerebellum. It
is predominantly expressed in neurons and to a lesser extent in glial cells. Apart from
the predominant 140 amino acid protein, there are at least two other alternatively
spliced variants of the protein; the 126 amino acid and 112 amino acid variants that
lack exon 3 and exon 5, respectively [<xref ref-type="bibr" rid="B9">9</xref>]. The
&#x003b1;-synuclein protein has three distinct structural domains. The amphipathic
N-terminal region (residues 1 to 60) contains 11 amino acid repeats including the
consensus sequence KTKEGV, which is important in &#x003b1;-helix formation [<xref ref-type="bibr" rid="B10">10</xref>]. The central hydrophobic region (residues 61 to 95)
contains the nonamyloid component region, which is important in protein aggregation
[<xref ref-type="bibr" rid="B4">4</xref>]. Finally, the C-terminal region
(residues 96 to 140) is highly acidic and proline rich.</p><p>&#x003b1;-Synuclein is encoded by the <italic>SNCA</italic> gene. PD genome-wide association
studies have shown that single nucleotide polymorphisms in <italic>SNCA</italic> are strongly
associated with an increased risk for idiopathic PD [<xref ref-type="bibr" rid="B11">11</xref>]-[<xref ref-type="bibr" rid="B14">14</xref>]. The <italic>SNCA</italic>
missense mutation Ala53Thr was the first causal mutation identified in dominantly
inherited PD [<xref ref-type="bibr" rid="B15">15</xref>]. Several <italic>SNCA</italic>
missense mutations (for example, Glu46Lys, His50Gln, Gly51Asp and Ala30Pro) have since
been identified in dominantly inherited PD [<xref ref-type="bibr" rid="B16">16</xref>]-[<xref ref-type="bibr" rid="B19">19</xref>]. In 1998 Conway
and colleagues demonstrated that <italic>SNCA</italic> missense mutations accelerated
&#x003b1;-synuclein fibril formation <italic>in vitro</italic>, implicating &#x003b1;-synuclein
misfolding and aggregation in PD pathogenesis [<xref ref-type="bibr" rid="B20">20</xref>]. <italic>SNCA</italic> duplication and triplication have also been
identified in PD subjects [<xref ref-type="bibr" rid="B21">21</xref>]-[<xref ref-type="bibr" rid="B25">25</xref>].</p><p>Although the exact function of &#x003b1;-synuclein is unknown, &#x003b1;-synuclein is thought
to play a role in maintaining a supply of synaptic vesicles in mature presynaptic
terminals, because its expression was detected only after synaptic development
[<xref ref-type="bibr" rid="B26">26</xref>]. <italic>In vitro</italic> knockdown studies
showed that &#x003b1;-synuclein regulates the quantity of different pools of synaptic
vesicles in mature neurons [<xref ref-type="bibr" rid="B26">26</xref>], influencing
synaptic activity as a molecular chaperone in the formation of SNARE complexes
[<xref ref-type="bibr" rid="B27">27</xref>], a requirement for presynaptic nerve
terminal release of neurotransmitters [<xref ref-type="bibr" rid="B28">28</xref>]. In
this way, &#x003b1;-synuclein may regulate the release of dopamine in controlling voluntary
and involuntary movements, or might influence memory and cognitive function as shown in
<italic>SNCA</italic> knockout mice [<xref ref-type="bibr" rid="B29">29</xref>]. This
function of &#x003b1;-synuclein becomes more important during increased synaptic activity
and aging, and could be a contributory factor in neurodegeneration.</p></sec><sec><title>3 Posttranslational modification of &#x003b1;-synuclein</title><p>Posttranslational modification of &#x003b1;-synuclein is prevalent and altered
&#x003b1;-synuclein proteins impact on a number of pathological processes, including
&#x003b1;-synuclein aggregation, Lewy body formation and neurotoxicity. The most common
posttranslational modification of &#x003b1;-synuclein is phosphorylation, which occurs
predominantly at serine residues S129 and, to a lesser extent, S87 and at tyrosine
residues Y125, Y133 and Y135 [<xref ref-type="bibr" rid="B30">30</xref>],[<xref ref-type="bibr" rid="B31">31</xref>]. In DLB brains, approximately 90% of insoluble
&#x003b1;-synuclein is phosphorylated at S129 compared with only 4% in soluble cytosolic
&#x003b1;-synuclein [<xref ref-type="bibr" rid="B32">32</xref>], implicating
phosphorylated &#x003b1;-synuclein in the process of &#x003b1;-synuclein aggregation.</p><p>The second most common posttranslational modification of &#x003b1;-synuclein is
ubiquitination &#x02013; the attachment of ubiquitin to &#x003b1;-synuclein at lysine
residues. Although &#x003b1;-synuclein contains 15 lysine residues, &#x003b1;-synuclein
isolated from Lewy bodies shows that the protein is ubiquitinated mainly at K6, K10 and
K12 residues. Ubiquitination of &#x003b1;-synuclein causes changes in &#x003b1;-synuclein
function/activity, impacting on &#x003b1;-synuclein localization and &#x003b1;-synuclein
degradation processes [<xref ref-type="bibr" rid="B33">33</xref>]-[<xref ref-type="bibr" rid="B35">35</xref>].</p><p>Another common posttranslational modification of &#x003b1;-synuclein is nitration &#x02013;
the attachment of a nitro molecule to &#x003b1;-synuclein at tyrosine residues (Y39, Y125,
Y133 and Y136). High concentrations of nitrated &#x003b1;-synuclein are found in Lewy
bodies [<xref ref-type="bibr" rid="B36">36</xref>]. Nitration of &#x003b1;-synuclein is
enhanced under conditions of elevated oxidative stress, which is widely regarded as an
important factor in Lewy body diseases. <italic>In vitro</italic> studies have shown that
nitration of &#x003b1;-synuclein induced &#x003b1;-synuclein oligomer formation and
mitochondrial impairment, leading to apoptosis via the integrin pathway [<xref ref-type="bibr" rid="B37">37</xref>]. In a PD cell model, nitration of &#x003b1;-synuclein
(via increased nitric oxide production) caused increases in the level of neurotoxic
&#x003b1;-synuclein species and cell death [<xref ref-type="bibr" rid="B38">38</xref>].</p></sec><sec><title>4 Prion-like propagation of &#x003b1;-synuclein</title><p>In 2008, two autopsy studies of patients with PD who survived more than 10&#x000a0;years
after receiving successful transplants of embryonic dopamine neurons to treat their
disease observed that the surviving transplanted neurons had &#x003b1;-synuclein
accumulation in typical Lewy bodies [<xref ref-type="bibr" rid="B39">39</xref>],[<xref ref-type="bibr" rid="B40">40</xref>]. The only way
these neurons could have such pathology was by a propagating mechanism, a concept of
transmission more commonly associated with prion diseases [<xref ref-type="bibr" rid="B41">41</xref>]. It should be noted that Braak and colleagues had in 2003
proposed a transmissible mechanism for &#x003b1;-synuclein propagation based on
observations that the disease seemed to start in the nose and/or gut and progress to
invade the brain in a staged manner [<xref ref-type="bibr" rid="B42">42</xref>],[<xref ref-type="bibr" rid="B43">43</xref>]. A number of
subsequent studies in animal and cell culture models have proven this concept of
transmission of &#x003b1;-synuclein between neurons, showing that exogenous
&#x003b1;-synuclein induces Lewy body pathology along neuroanatomical pathways in the brain
(for example [<xref ref-type="bibr" rid="B44">44</xref>]-[<xref ref-type="bibr" rid="B48">48</xref>]). It should be noted that it is the conformation of the
protein that is transmitted to endogenous protein residing within neurons, as in mouse
models the aggregates from exogenous sources disappear in about a week with endogenous
aggregates beginning around 3&#x000a0;months later [<xref ref-type="bibr" rid="B49">49</xref>]. This observation suggests that a particular strain of
&#x003b1;-synuclein is transmitted between neurons.</p><p>Consistent with the concept of different prion strains [<xref ref-type="bibr" rid="B50">50</xref>], a number of studies have now identified and characterized
different strains of &#x003b1;-synuclein. Strains made <italic>in vivo</italic> exhibit
fundamentally different properties, including the packing of their building blocks and
growth and amplification properties, as well as their tropism, cellular binding and
penetration properties and toxicity [<xref ref-type="bibr" rid="B51">51</xref>],[<xref ref-type="bibr" rid="B52">52</xref>]. These
differences can be exaggerated by modifying the solution concentration, molecular
crowding, agitation, temperature, pH and ionic strength [<xref ref-type="bibr" rid="B53">53</xref>]. Exogenous factors that accelerate the <italic>in vitro</italic>
aggregation of &#x003b1;-synuclein include agrochemicals, polycations, histones, metal
ions, glycosaminoglycans, sodium dodecyl sulfate and organic solvents, while factors
that inhibit &#x003b1;-synuclein aggregation include small chemical compounds, heat shock
proteins, PAMAM dendrimers, &#x003b2;-synuclein and &#x003b3;-synuclein, catecholamines,
phospholipids, rifampicin, trehalose and oxidative modifications [<xref ref-type="bibr" rid="B53">53</xref>]. The combination of different factors may impact on
the strains of &#x003b1;-synuclein in different people and may explain some of the
heterogeneity that is known both clinically and pathologically, and especially in the
dynamics of the different types of Lewy body diseases [<xref ref-type="bibr" rid="B54">54</xref>]. Morphological and structural differences have been noted in
patients with Lewy bodies consistent with the concept of different &#x003b1;-synuclein
strains &#x02013; Lewy bodies in the brainstem are morphologically different from those in
the cortex [<xref ref-type="bibr" rid="B55">55</xref>], and conformationally different
strains of &#x003b1;-synuclein have been identified from cortical tissue samples of
patients with PD depending on the presence or absence of Alzheimer pathologies
[<xref ref-type="bibr" rid="B52">52</xref>].</p></sec><sec><title>5 Binding and interaction of &#x003b1;-synuclein with lipid membranes</title><p>Under normal conditions, &#x003b1;-synuclein exists as a randomly structured and natively
unfolded protein and remains as a monomer within the cytoplasm. Under pathological
conditions, however, &#x003b1;-synuclein undergoes structural/conformational changes
causing the monomers to aggregate with each other and become insoluble. Much evidence
suggests that changes to the &#x003b1;-synuclein structure and properties are initiated
when the protein binds and interacts with lipid surfaces, such as lipid droplets,
phospholipid bilayers or lipid membranes. When &#x003b1;-synuclein monomers, isolated from
human neurons, were exposed to synthetic lipid membranes, they readily bound to the
membrane surface and formed dimers and oligomers [<xref ref-type="bibr" rid="B56">56</xref>],[<xref ref-type="bibr" rid="B57">57</xref>]. Such an
interaction is thought to induce a dramatic change in &#x003b1;-synuclein structure from
its unfolded form to a folded &#x003b1;-helical secondary structure [<xref ref-type="bibr" rid="B57">57</xref>]. The imperfect repeats of 11 amino acids present in
&#x003b1;-synuclein, similar to the amphipathic &#x003b1;-helical motif common to
apolipoproteins and other lipid-binding proteins, appear to play an important role in
the lipid membrane binding process [<xref ref-type="bibr" rid="B58">58</xref>]. What is
significant about such a change is that the &#x003b1;-helical form of &#x003b1;-synuclein is
prone to forming different types of oligomers, the species that are thought to be toxic
to cells. The lipid composition of membranes has been shown to affect the
binding/interaction of &#x003b1;-synuclein to the membrane and subsequent oligomerization
[<xref ref-type="bibr" rid="B56">56</xref>],[<xref ref-type="bibr" rid="B59">59</xref>]. &#x003b1;-Synuclein is thought to preferentially bind to regions
of membranes that are enriched in lipids [<xref ref-type="bibr" rid="B60">60</xref>].
These regions are called lipid rafts and are characterized by high concentrations of
cholesterol and sphingolipids and altered surface charge that may favor &#x003b1;-synuclein
binding. The lipid rafts appear to serve as a platform that promotes &#x003b1;-synuclein
binding and oligomerization.</p><p>Contrary to overwhelming evidence that &#x003b1;-synuclein exists as an unfolded monomer in
the cytosol, Bartels and colleagues reported that endogenous &#x003b1;-synuclein exists
predominantly as a folded tetramer (~58&#x000a0;kDa) [<xref ref-type="bibr" rid="B61">61</xref>]. The explanation provided by the authors for this apparent
difference is that most studies claiming the unfolded monomer hypothesis commonly use
sample heating and denaturing gels to analyze &#x003b1;-synuclein, whereas the authors used
nondenaturing conditions. They have also provided evidence by other means &#x02013; that
is, scanning transmission electron microscopy and cell cross-linking &#x02013; to confirm
the prevalence of &#x003b1;-synuclein tetramer in neurons and human brain tissues
[<xref ref-type="bibr" rid="B61">61</xref>]. Bartels and colleagues proposed that
since &#x003b1;-synuclein tetramers are less likely to form aggregates, the tetramers first
undergo destabilization prior to forming aggregates. The authors suggested that
stabilizing the physiological tetramers could reduce &#x003b1;-synuclein pathogenicity in
PD and other &#x003b1;-synucleinopathies.</p></sec><sec><title>6 Dementia with Lewy bodies</title><p>DLB was initially identified as a dementia syndrome with Lewy body pathology
[<xref ref-type="bibr" rid="B62">62</xref>], which is now incorporated in the
<italic>Diagnostic and Statistical Manual</italic> criteria as a clinical disease entity
(neurocognitive disorder with Lewy bodies). Current objective data suggest that the
sensitivity of accurate clinical diagnosis is very low, however, with most clinical
cases identified actually having AD rather than DLB at autopsy [<xref ref-type="bibr" rid="B63">63</xref>]-[<xref ref-type="bibr" rid="B68">68</xref>], and therefore
current diagnostic criteria for DLB exclude cases with coexisting AD pathology
[<xref ref-type="bibr" rid="B62">62</xref>]. Although DLB remains easy to
identify pathologically with different cellular pathologies differentiating it from
other dementia syndromes, pathological identification using only Lewy body pathology has
been shown to be inaccurate due to overlap with patients without dementia symptoms.
Current neuropathological criteria state that neurocognitive syndromes with Lewy bodies
are most likely when Lewy bodies are prevalent in at least limbic brain regions, but are
also often found in association neocortices [<xref ref-type="bibr" rid="B69">69</xref>]. A number of studies have shown that a combination of cellular
pathologies, which include &#x003b1;-synuclein and &#x003b2;-amyloid deposition as well as
dopamine denervation, assist with differentiating this dementia syndrome from others
[<xref ref-type="bibr" rid="B54">54</xref>]. Approximately 25% of DLB patients
display significant parkinsonian symptoms at the onset of disease, consistent with an
early dopamine denervation, whereas 25% of DLB patients never develop any parkinsonian
symptoms and have less significant dopamine loss. DLB is best conceptualized as a
dominant dementia syndrome with multiple pathologies that include Lewy bodies and more
frequently has multiple pathologies compared with AD [<xref ref-type="bibr" rid="B70">70</xref>]. The diversity of clinical phenotypes associated with DLB is
likely to reflect the timing and different combinations of these pathologies within
different brain regions.</p><p>Because of the difficulty in obtaining clinically proven cases with pathological DLB,
studies of the underlying molecular changes in the brain are rare. Interesting
pathological differences have been noted &#x02013; the longer the duration of parkinsonism
prior to dementia onset, the less severe the cortical &#x003b1;-synuclein and
&#x003b2;-amyloid deposition as well as the cortical cholinergic deficit [<xref ref-type="bibr" rid="B71">71</xref>]. DLB patients present significant cholinergic
deficits [<xref ref-type="bibr" rid="B72">72</xref>]-[<xref ref-type="bibr" rid="B74">74</xref>] and a decrease in serum &#x003b1;-synuclein [<xref ref-type="bibr" rid="B75">75</xref>].</p></sec><sec><title>7 Parkinson&#x02019;s disease and Parkinson&#x02019;s disease dementia</title><p>In contrast to DLB, which is a dominant dementia syndrome, PD is a dominant movement
disorder characterized by the presence of two of four cardinal signs (that is,
bradykinesia, rigidity, resting tremor, gait instability) that are responsive to
levodopa therapy [<xref ref-type="bibr" rid="B76">76</xref>]. Current neuropathological
criteria require moderate to severe loss of pigmented dopamine neurons in the substantia
nigra along with Lewy bodies at least in the brainstem [<xref ref-type="bibr" rid="B69">69</xref>]. PDD was defined in 2007 as a dementia syndrome in patients
with an initial diagnosis of PD for more than 1&#x000a0;year [<xref ref-type="bibr" rid="B77">77</xref>] and, as stated above for DLB, the cognitive symptoms are
thought to occur when Lewy bodies are prevalent in at least limbic brain regions, but
often also in association neocortices [<xref ref-type="bibr" rid="B69">69</xref>]. A
smaller proportion of people with PDD have multiple pathologies [<xref ref-type="bibr" rid="B78">78</xref>] as observed in most DLB cases (see above).</p><p>Changes in the phosphorylation and solubility of &#x003b1;-synuclein occur prior to Lewy
body formation in PD and PDD [<xref ref-type="bibr" rid="B79">79</xref>]-[<xref ref-type="bibr" rid="B81">81</xref>]. In terms of solubility, the amount of soluble
&#x003b1;-synuclein is not substantially increased and actually decreases slightly over the
course of PD [<xref ref-type="bibr" rid="B79">79</xref>],[<xref ref-type="bibr" rid="B82">82</xref>]. The levels of phosphorylation of &#x003b1;-synuclein greatly
increase prior to Lewy body formation [<xref ref-type="bibr" rid="B79">79</xref>]-[<xref ref-type="bibr" rid="B81">81</xref>] and the Lewy
body formation correlates with an enhanced lipid association of &#x003b1;-synuclein
[<xref ref-type="bibr" rid="B79">79</xref>]. In a longitudinal study of patients
with PD it took an average 13&#x000a0;years for the propagation of Lewy body aggregates to
reach limbic brain regions, and 18&#x000a0;years before aggregates occurred in association
cortices in 50% of PD cases [<xref ref-type="bibr" rid="B83">83</xref>]. These studies
show that the intracellular changes in &#x003b1;-synuclein take considerable time to
propagate and that posttranslational modifications of &#x003b1;-synuclein are substantial
prior to its irreversible fibrilization.</p></sec><sec><title>8 Multiple system atrophy</title><p>MSA is a rapidly progressive neurodegenerative disease characterized by the clinical
triad of parkinsonism (similar to PD), cerebellar ataxia and autonomic failure. The
distribution of pathology classically encompasses three functional systems in the
central nervous system &#x02013; the striatonigral system, the olivopontocerebellar system
and the autonomic system &#x02013; impacting on movement, muscle control, blood pressure,
heart rate and bladder function [<xref ref-type="bibr" rid="B84">84</xref>],[<xref ref-type="bibr" rid="B85">85</xref>]. Like PD and
DLB, the dominant histopathology of MSA is the presence of misfolded and fibrillar
&#x003b1;-synuclein in the cytoplasm. However, unlike PD and DLB, the principal site for
&#x003b1;-synuclein deposition is in the oligodendrocytes rather than neurons. Based on
current information, the sequence of pathological events in MSA is now recognized as
myelin dysregulation first, followed by demyelination and then neurodegeneration and
loss of neurons [<xref ref-type="bibr" rid="B86">86</xref>]-[<xref ref-type="bibr" rid="B88">88</xref>]; neurodegeneration therefore appears to be a secondary effect
in MSA.</p><p>No causal mutations or multiplications of the coding sequence of &#x003b1;-synuclein have
been identified in MSA cases [<xref ref-type="bibr" rid="B89">89</xref>]-[<xref ref-type="bibr" rid="B91">91</xref>], although the search is not exhaustive because MSA
is a rare disease. Earlier studies, based on small numbers of MSA cases, have reported
that genetic variants of <italic>SNCA</italic> were associated with MSA [<xref ref-type="bibr" rid="B92">92</xref>]-[<xref ref-type="bibr" rid="B94">94</xref>]; however, a
recent pioneering genome-wide association study of 918 MSA cases and 3,884 controls
found no risk-conferring loci on the <italic>SNCA</italic> gene [<xref ref-type="bibr" rid="B95">95</xref>]. Posttranslational modification studies of &#x003b1;-synuclein
in MSA have shown that phosphorylation and ubiquitination are implicated in the
deposition of &#x003b1;-synuclein [<xref ref-type="bibr" rid="B96">96</xref>], although no
definitively causative relationships have yet been established. Furthermore, the origin
of &#x003b1;-synuclein in oligodendrocytes remains stubbornly enigmatic. Although the
evidence of significant physiological expression of &#x003b1;-synuclein in mature
oligodendrocytes is conflicting [<xref ref-type="bibr" rid="B97">97</xref>]-[<xref ref-type="bibr" rid="B99">99</xref>], it has been
proposed that upregulation of the <italic>SNCA</italic> gene in these cells could be the cause
of &#x003b1;-synuclein aggregation. Nevertheless, successful animal models of MSA, which
recapitulate both neuropathological and clinical features, have been generated by
overexpression of &#x003b1;-synuclein in the oligodendrocytes [<xref ref-type="bibr" rid="B96">96</xref>],[<xref ref-type="bibr" rid="B100">100</xref>],[<xref ref-type="bibr" rid="B101">101</xref>]. Alternatively, aberrant uptake of
&#x003b1;-synuclein from the extracellular environment has also been proposed as a possible
mechanism of &#x003b1;-synuclein aggregation in oligodendrocytes [<xref ref-type="bibr" rid="B97">97</xref>],[<xref ref-type="bibr" rid="B102">102</xref>],[<xref ref-type="bibr" rid="B103">103</xref>].</p></sec><sec><title>9 Lewy body pathology in Alzheimer&#x02019;s disease</title><p>Although Lewy bodies are the pathological hallmark of PD and DLB, recent studies suggest
a considerable proportion of AD brains show &#x003b1;-synuclein pathology. In a recent
study of 22 clinically diagnosed cases of AD, 10 were found to have &#x003b1;-synuclein
immunoreactive Lewy bodies by subsequent pathological examination [<xref ref-type="bibr" rid="B104">104</xref>]. Other studies showed that as many as one-half of
patients with AD, including both sporadic and familial cases, have &#x003b1;-synuclein
aggregates [<xref ref-type="bibr" rid="B2">2</xref>],[<xref ref-type="bibr" rid="B105">105</xref>]-[<xref ref-type="bibr" rid="B107">107</xref>]. In these
studies, &#x003b1;-synuclein aggregates were mostly restricted to the amygdala, implying
that the spread of &#x003b1;-synuclein inclusions is different to that of PD. Lewy
pathology in AD has also been reported to be formed mainly in the cell body of neurons,
and not in the axonal terminals and dendrites as in PD [<xref ref-type="bibr" rid="B107">107</xref>],[<xref ref-type="bibr" rid="B108">108</xref>]. The Lewy
pathology therefore possibly mirrors a nonspecific end stage of AD. However, genetic or
lifestyle factors might prime neurons to accumulate &#x003b1;-synuclein aggregates in a
subset of AD patients, and thus &#x003b1;-synuclein aggregates might reflect a causal
pathogenic mechanism in AD.</p><p>Several studies show that high levels of AD pathology are often observed in patients
with PD and DLB [<xref ref-type="bibr" rid="B78">78</xref>] and correlate with the
decline in cognitive function more than the amount of &#x003b1;-synuclein aggregates
[<xref ref-type="bibr" rid="B109">109</xref>]-[<xref ref-type="bibr" rid="B111">111</xref>]. Interestingly, PD/DLB cases with AD pathology have higher
&#x003b1;-synuclein levels in cortical and limbic areas than cases without AD pathology
[<xref ref-type="bibr" rid="B112">112</xref>], which implies a possible
interaction between &#x003b1;-synuclein and AD pathology in these disorders. How the
pathologies of &#x003b1;-synuclein, &#x003b2;-amyloid and tau relate to each other in PD and
AD is poorly understood. Recent work using a transgenic mouse model of DLB-AD provides
some clues to the interaction between &#x003b2;-amyloid, tau and &#x003b1;-synuclein
[<xref ref-type="bibr" rid="B113">113</xref>]. This mouse model was generated
from a cross between 3&#x02009;&#x000d7;&#x02009;Tg-AD mice and mice that express the A53T
mutation in &#x003b1;-synuclein [<xref ref-type="bibr" rid="B114">114</xref>]. The DLB-AD
mice exhibited accelerated cognitive decline, compared with 3&#x02009;&#x000d7;&#x02009;Tg-AD
mice alone, with more severe &#x003b2;-amyloid, tau and &#x003b1;-synuclein pathologies
[<xref ref-type="bibr" rid="B113">113</xref>]. These data suggest that the three
pathologies interact and somehow enhance each other, resulting in accelerated cognitive
dysfunction.</p></sec><sec><title>10 Therapeutic strategies</title><p>Because of the marked cholinergic deficit associated with DLB (see above),
cholinesterase inhibitors are routinely used for clinical improvement [<xref ref-type="bibr" rid="B115">115</xref>]. In PDD these agents have been shown to improve
cognitive function, behavioral disturbances and activities of daily living
[<xref ref-type="bibr" rid="B115">115</xref>]. Their effect in DLB is less clear
[<xref ref-type="bibr" rid="B115">115</xref>], potentially because DLB is poorly
diagnosed clinically and often has multiple underlying pathologies (see above).
Interestingly, successful treatment with cholinesterase inhibitors was shown to decrease
&#x003b2;-amyloid deposition in a small study of DLB patients [<xref ref-type="bibr" rid="B116">116</xref>], suggesting that these drugs have mechanistic as well as
symptomatic effects. Considering the molecular events surrounding &#x003b1;-synuclein
deposition, a number of strategies are being developed [<xref ref-type="bibr" rid="B117">117</xref>],[<xref ref-type="bibr" rid="B118">118</xref>]. These
strategies include small anti-aggregating molecules and chaperones [<xref ref-type="bibr" rid="B119">119</xref>]-[<xref ref-type="bibr" rid="B123">123</xref>],
but perhaps the most promising strategy is the development of antibody therapies for
&#x003b1;-synuclein. These therapies target extracellular &#x003b1;-synuclein binding the
protein to reduce its self-aggregation and increase its clearance, with a number of
antibodies already in production [<xref ref-type="bibr" rid="B124">124</xref>]-[<xref ref-type="bibr" rid="B127">127</xref>]. Another
promising development is the use of the &#x003b2;-lactum antibiotic ceftriaxone as a
therapeutic agent to block &#x003b1;-synuclein aggregation [<xref ref-type="bibr" rid="B128">128</xref>], although the macrocyclic antibiotic rifampicin has not been
successful in MSA [<xref ref-type="bibr" rid="B129">129</xref>].</p></sec><sec><title>11 Conclusions</title><p>The assessment of different &#x003b1;-synucleinopathies focuses on a variety of mechanisms
that affect the pathogenesis of Lewy body diseases. While all &#x003b1;-synucleinopathies
are characterized by &#x003b1;-synuclein aggregates with similar posttranslational
modifications and lipid associations, the cell type involved, their location and their
association with other protein depositions vary substantially, and recent data suggest
that perhaps the strain of &#x003b1;-synuclein involved may also differ. An increase in
&#x003b1;-synuclein is hypothesized to precipitate the protein&#x02019;s aggregation, and
this is evident in some familial forms of PD, but the precipitating events for most of
the &#x003b1;-synucleinopathies remain to be determined. It is clear for Lewy body
disorders that the neuronal propagation can be slow or rapid, and is impacted on by AD
pathology; however, Lewy bodies in AD are focused in the amygdala, suggesting that the
initiating region of &#x003b1;-synuclein aggregation in the brain can be diverse.
Importantly, the concept of propagation of &#x003b1;-synuclein pathology between neurons
has resulted in the development of new therapies that target this mechanism with the
potential to halt or slow this aspect of Lewy body diseases.</p><boxed-text><caption><title>Note</title></caption><p>This article is part of a series on <italic>Lewy Body Dementia</italic>, edited by Ian McKeith
and James Galvin. Other articles in this series can be found at
<ext-link ext-link-type="uri" xlink:href="http://alzres.com/series/LewyBodyDementia">http://alzres.com/series/LewyBodyDementia</ext-link>.</p></boxed-text></sec><sec><title>Abbreviations</title><p>AD: Alzheimer&#x02019;s disease</p><p>DLB: Dementia with Lewy bodies</p><p>MSA: Multiple system atrophy</p><p>PD: Parkinson&#x02019;s disease</p><p>PDD: Parkinson&#x02019;s disease dementia</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec></body><back><sec><title>Acknowledgements</title><p>This work was supported by a National Health and Medical Research Council of
Australia (NHMRC) project grant (#1022325). GMH is a NHMRC Senior Principal Research
Fellow (#630434).</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Ueda</surname><given-names>K</given-names></name><name><surname>Fukushima</surname><given-names>H</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Iwai</surname><given-names>A</given-names></name><name><surname>Yoshimoto</surname><given-names>M</given-names></name><name><surname>Otero</surname><given-names>DA</given-names></name><name><surname>Kondo</surname><given-names>J</given-names></name><name><surname>Ihara</surname><given-names>Y</given-names></name><name><surname>Saitoh</surname><given-names>T</given-names></name><article-title>Molecular cloning of cDNA encoding an unrecognized component of amyloid in
Alzheimer disease</article-title><source>Proc Natl Acad Sci U S A</source><year>1993</year><volume>90</volume><fpage>11282</fpage><lpage>11286</lpage><pub-id pub-id-type="pmid">8248242</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Lippa</surname><given-names>CF</given-names></name><name><surname>Fujiwara</surname><given-names>H</given-names></name><name><surname>Mann</surname><given-names>DM</given-names></name><name><surname>Giasson</surname><given-names>B</given-names></name><name><surname>Baba</surname><given-names>M</given-names></name><name><surname>Schmidt</surname><given-names>ML</given-names></name><name><surname>Nee</surname><given-names>LE</given-names></name><name><surname>O'Connell</surname><given-names>B</given-names></name><name><surname>Pollen</surname><given-names>DA</given-names></name><name><surname>St George-Hyslop</surname><given-names>P</given-names></name><name><surname>Ghetti</surname><given-names>B</given-names></name><name><surname>Nochlin</surname><given-names>D</given-names></name><name><surname>Bird</surname><given-names>TD</given-names></name><name><surname>Cairns</surname><given-names>NJ</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name><name><surname>Iwatsubo</surname><given-names>T</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><article-title>Lewy bodies contain altered alpha-synuclein in brains of many familial
Alzheimer&#x02019;s disease patients with mutations in presenilin and amyloid
precursor protein genes</article-title><source>Am J Pathol</source><year>1998</year><volume>153</volume><fpage>1365</fpage><lpage>1370</lpage><pub-id pub-id-type="pmid">9811326</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Arai</surname><given-names>Y</given-names></name><name><surname>Yamazaki</surname><given-names>M</given-names></name><name><surname>Mori</surname><given-names>O</given-names></name><name><surname>Muramatsu</surname><given-names>H</given-names></name><name><surname>Asano</surname><given-names>G</given-names></name><name><surname>Katayama</surname><given-names>Y</given-names></name><article-title>Alpha-synuclein-positive structures in cases with sporadic Alzheimer&#x02019;s
disease: morphology and its relationship to tau aggregation</article-title><source>Brain Res</source><year>2001</year><volume>888</volume><fpage>287</fpage><lpage>296</lpage><pub-id pub-id-type="pmid">11150486</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Spillantini</surname><given-names>MG</given-names></name><name><surname>Schmidt</surname><given-names>ML</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Jakes</surname><given-names>R</given-names></name><name><surname>Goedert</surname><given-names>M</given-names></name><article-title>Alpha-synuclein in Lewy bodies</article-title><source>Nature</source><year>1997</year><volume>388</volume><fpage>839</fpage><lpage>840</lpage><pub-id pub-id-type="pmid">9278044</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Gai</surname><given-names>WP</given-names></name><name><surname>Power</surname><given-names>JH</given-names></name><name><surname>Blumbergs</surname><given-names>PC</given-names></name><name><surname>Blessing</surname><given-names>WW</given-names></name><article-title>Multiple-system atrophy: a new alpha-synuclein disease?</article-title><source>Lancet</source><year>1998</year><volume>352</volume><fpage>547</fpage><lpage>548</lpage><pub-id pub-id-type="pmid">9716068</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Newell</surname><given-names>KL</given-names></name><name><surname>Boyer</surname><given-names>P</given-names></name><name><surname>Gomez-Tortosa</surname><given-names>E</given-names></name><name><surname>Hobbs</surname><given-names>W</given-names></name><name><surname>Hedley-Whyte</surname><given-names>ET</given-names></name><name><surname>Vonsattel</surname><given-names>JP</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><article-title>Alpha-synuclein immunoreactivity is present in axonal swellings in neuroaxonal
dystrophy and acute traumatic brain injury</article-title><source>J Neuropathol Exp Neurol</source><year>1999</year><volume>58</volume><fpage>1263</fpage><lpage>1268</lpage><pub-id pub-id-type="pmid">10604751</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Wolozin</surname><given-names>B</given-names></name><name><surname>Behl</surname><given-names>C</given-names></name><article-title>Mechanisms of neurodegenerative disorders: part 1: protein aggregates</article-title><source>Arch Neurol</source><year>2000</year><volume>57</volume><fpage>793</fpage><lpage>796</lpage><pub-id pub-id-type="pmid">10867775</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Lashuel</surname><given-names>HA</given-names></name><name><surname>Overk</surname><given-names>CR</given-names></name><name><surname>Oueslati</surname><given-names>A</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><article-title>The many faces of alpha-synuclein: from structure and toxicity to therapeutic
target</article-title><source>Nat Rev Neurosci</source><year>2013</year><volume>14</volume><fpage>38</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">23254192</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Beyer</surname><given-names>K</given-names></name><article-title>Alpha-synuclein structure, posttranslational modification and alternative splicing
as aggregation enhancers</article-title><source>Acta Neuropathol</source><year>2006</year><volume>112</volume><fpage>237</fpage><lpage>251</lpage><pub-id pub-id-type="pmid">16845533</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Clayton</surname><given-names>DF</given-names></name><name><surname>George</surname><given-names>JM</given-names></name><article-title>The synucleins: a family of proteins involved in synaptic function, plasticity,
neurodegeneration and disease</article-title><source>Trends Neurosci</source><year>1998</year><volume>21</volume><fpage>249</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">9641537</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Pals</surname><given-names>P</given-names></name><name><surname>Lincoln</surname><given-names>S</given-names></name><name><surname>Manning</surname><given-names>J</given-names></name><name><surname>Heckman</surname><given-names>M</given-names></name><name><surname>Skipper</surname><given-names>L</given-names></name><name><surname>Hulihan</surname><given-names>M</given-names></name><name><surname>Van den Broeck</surname><given-names>M</given-names></name><name><surname>De Pooter</surname><given-names>T</given-names></name><name><surname>Cras</surname><given-names>P</given-names></name><name><surname>Crook</surname><given-names>J</given-names></name><name><surname>Van Broeckhoven</surname><given-names>C</given-names></name><name><surname>Farrer</surname><given-names>MJ</given-names></name><article-title>alpha-Synuclein promoter confers susceptibility to Parkinson&#x02019;s disease</article-title><source>Ann Neurol</source><year>2004</year><volume>56</volume><fpage>591</fpage><lpage>595</lpage><pub-id pub-id-type="pmid">15455394</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Rajput</surname><given-names>A</given-names></name><name><surname>Vilarino-Guell</surname><given-names>C</given-names></name><name><surname>Rajput</surname><given-names>ML</given-names></name><name><surname>Ross</surname><given-names>OA</given-names></name><name><surname>Soto-Ortolaza</surname><given-names>AI</given-names></name><name><surname>Lincoln</surname><given-names>SJ</given-names></name><name><surname>Cobb</surname><given-names>SA</given-names></name><name><surname>Heckman</surname><given-names>MG</given-names></name><name><surname>Farrer</surname><given-names>MJ</given-names></name><article-title>Alpha-synuclein polymorphisms are associated with Parkinson&#x02019;s disease in a
Saskatchewan population</article-title><source>Mov Disord</source><year>2009</year><volume>24</volume><fpage>2411</fpage><lpage>2414</lpage><pub-id pub-id-type="pmid">19890971</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Pankratz</surname><given-names>N</given-names></name><name><surname>Wilk</surname><given-names>JB</given-names></name><name><surname>Latourelle</surname><given-names>JC</given-names></name><name><surname>DeStefano</surname><given-names>AL</given-names></name><name><surname>Halter</surname><given-names>C</given-names></name><name><surname>Pugh</surname><given-names>EW</given-names></name><name><surname>Doheny</surname><given-names>KF</given-names></name><name><surname>Gusella</surname><given-names>JF</given-names></name><name><surname>Nichols</surname><given-names>WC</given-names></name><name><surname>Foroud</surname><given-names>T</given-names></name><name><surname>Myers</surname><given-names>RH</given-names></name><article-title>Genome-wide association study for susceptibility genes contributing to familial
Parkinson disease</article-title><source>Hum Genet</source><year>2009</year><volume>124</volume><fpage>593</fpage><lpage>605</lpage><pub-id pub-id-type="pmid">18985386</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Maraganore</surname><given-names>DM</given-names></name><name><surname>de Andrade</surname><given-names>M</given-names></name><name><surname>Elbaz</surname><given-names>A</given-names></name><name><surname>Farrer</surname><given-names>MJ</given-names></name><name><surname>Ioannidis</surname><given-names>JP</given-names></name><name><surname>Kruger</surname><given-names>R</given-names></name><name><surname>Rocca</surname><given-names>WA</given-names></name><name><surname>Schneider</surname><given-names>NK</given-names></name><name><surname>Lesnick</surname><given-names>TG</given-names></name><name><surname>Lincoln</surname><given-names>SJ</given-names></name><name><surname>Hulihan</surname><given-names>MM</given-names></name><name><surname>Aasly</surname><given-names>JO</given-names></name><name><surname>Ashizawa</surname><given-names>T</given-names></name><name><surname>Chartier-Harlin</surname><given-names>MC</given-names></name><name><surname>Checkoway</surname><given-names>H</given-names></name><name><surname>Ferrarese</surname><given-names>C</given-names></name><name><surname>Hadjigeorgiou</surname><given-names>G</given-names></name><name><surname>Hattori</surname><given-names>N</given-names></name><name><surname>Kawakami</surname><given-names>H</given-names></name><name><surname>Lambert</surname><given-names>JC</given-names></name><name><surname>Lynch</surname><given-names>T</given-names></name><name><surname>Mellick</surname><given-names>GD</given-names></name><name><surname>Papapetropoulos</surname><given-names>S</given-names></name><name><surname>Parsian</surname><given-names>A</given-names></name><name><surname>Quattrone</surname><given-names>A</given-names></name><name><surname>Riess</surname><given-names>O</given-names></name><name><surname>Tan</surname><given-names>EK</given-names></name><name><surname>Van Broeckhoven</surname><given-names>C</given-names></name><article-title>Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson
disease</article-title><source>JAMA</source><year>2006</year><volume>296</volume><fpage>661</fpage><lpage>670</lpage><pub-id pub-id-type="pmid">16896109</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Polymeropoulos</surname><given-names>MH</given-names></name><name><surname>Lavedan</surname><given-names>C</given-names></name><name><surname>Leroy</surname><given-names>E</given-names></name><name><surname>Ide</surname><given-names>SE</given-names></name><name><surname>Dehejia</surname><given-names>A</given-names></name><name><surname>Dutra</surname><given-names>A</given-names></name><name><surname>Pike</surname><given-names>B</given-names></name><name><surname>Root</surname><given-names>H</given-names></name><name><surname>Rubenstein</surname><given-names>J</given-names></name><name><surname>Boyer</surname><given-names>R</given-names></name><name><surname>Stenroos</surname><given-names>ES</given-names></name><name><surname>Chandrasekharappa</surname><given-names>S</given-names></name><name><surname>Athanassiadou</surname><given-names>A</given-names></name><name><surname>Papapetropoulos</surname><given-names>T</given-names></name><name><surname>Johnson</surname><given-names>WG</given-names></name><name><surname>Lazzarini</surname><given-names>AM</given-names></name><name><surname>Duvoisin</surname><given-names>RC</given-names></name><name><surname>Di Iorio</surname><given-names>G</given-names></name><name><surname>Golbe</surname><given-names>LI</given-names></name><name><surname>Nussbaum</surname><given-names>RL</given-names></name><article-title>Mutation in the alpha-synuclein gene identified in families with Parkinson&#x02019;s
disease</article-title><source>Science</source><year>1997</year><volume>276</volume><fpage>2045</fpage><lpage>2047</lpage><pub-id pub-id-type="pmid">9197268</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Kruger</surname><given-names>R</given-names></name><name><surname>Kuhn</surname><given-names>W</given-names></name><name><surname>Muller</surname><given-names>T</given-names></name><name><surname>Woitalla</surname><given-names>D</given-names></name><name><surname>Graeber</surname><given-names>M</given-names></name><name><surname>Kosel</surname><given-names>S</given-names></name><name><surname>Przuntek</surname><given-names>H</given-names></name><name><surname>Epplen</surname><given-names>JT</given-names></name><name><surname>Schols</surname><given-names>L</given-names></name><name><surname>Riess</surname><given-names>O</given-names></name><article-title>Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson&#x02019;s
disease</article-title><source>Nat Genet</source><year>1998</year><volume>18</volume><fpage>106</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">9462735</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Zarranz</surname><given-names>JJ</given-names></name><name><surname>Alegre</surname><given-names>J</given-names></name><name><surname>Gomez-Esteban</surname><given-names>JC</given-names></name><name><surname>Lezcano</surname><given-names>E</given-names></name><name><surname>Ros</surname><given-names>R</given-names></name><name><surname>Ampuero</surname><given-names>I</given-names></name><name><surname>Vidal</surname><given-names>L</given-names></name><name><surname>Hoenicka</surname><given-names>J</given-names></name><name><surname>Rodriguez</surname><given-names>O</given-names></name><name><surname>Atares</surname><given-names>B</given-names></name><name><surname>Llorens</surname><given-names>V</given-names></name><name><surname>Gomez Tortosa</surname><given-names>E</given-names></name><name><surname>del Ser</surname><given-names>T</given-names></name><name><surname>Munoz</surname><given-names>DG</given-names></name><name><surname>de Yebenes</surname><given-names>JG</given-names></name><article-title>The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body
dementia</article-title><source>Ann Neurol</source><year>2004</year><volume>55</volume><fpage>164</fpage><lpage>173</lpage><pub-id pub-id-type="pmid">14755719</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Proukakis</surname><given-names>C</given-names></name><name><surname>Dudzik</surname><given-names>CG</given-names></name><name><surname>Brier</surname><given-names>T</given-names></name><name><surname>MacKay</surname><given-names>DS</given-names></name><name><surname>Cooper</surname><given-names>JM</given-names></name><name><surname>Millhauser</surname><given-names>GL</given-names></name><name><surname>Houlden</surname><given-names>H</given-names></name><name><surname>Schapira</surname><given-names>AH</given-names></name><article-title>A novel alpha-synuclein missense mutation in Parkinson disease</article-title><source>Neurology</source><year>2013</year><volume>80</volume><fpage>1062</fpage><lpage>1064</lpage><pub-id pub-id-type="pmid">23427326</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Lesage</surname><given-names>S</given-names></name><name><surname>Anheim</surname><given-names>M</given-names></name><name><surname>Letournel</surname><given-names>F</given-names></name><name><surname>Bousset</surname><given-names>L</given-names></name><name><surname>Honore</surname><given-names>A</given-names></name><name><surname>Rozas</surname><given-names>N</given-names></name><name><surname>Pieri</surname><given-names>L</given-names></name><name><surname>Madiona</surname><given-names>K</given-names></name><name><surname>Durr</surname><given-names>A</given-names></name><name><surname>Melki</surname><given-names>R</given-names></name><name><surname>Verny</surname><given-names>C</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name><article-title>G51D alpha-synuclein mutation causes a novel Parkinsonian-pyramidal syndrome</article-title><source>Ann Neurol</source><year>2013</year><volume>73</volume><fpage>459</fpage><lpage>471</lpage><pub-id pub-id-type="pmid">23526723</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Conway</surname><given-names>KA</given-names></name><name><surname>Harper</surname><given-names>JD</given-names></name><name><surname>Lansbury</surname><given-names>PT</given-names></name><article-title>Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to
early-onset Parkinson disease</article-title><source>Nat Med</source><year>1998</year><volume>4</volume><fpage>1318</fpage><lpage>1320</lpage><pub-id pub-id-type="pmid">9809558</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Singleton</surname><given-names>AB</given-names></name><name><surname>Farrer</surname><given-names>M</given-names></name><name><surname>Johnson</surname><given-names>J</given-names></name><name><surname>Singleton</surname><given-names>A</given-names></name><name><surname>Hague</surname><given-names>S</given-names></name><name><surname>Kachergus</surname><given-names>J</given-names></name><name><surname>Hulihan</surname><given-names>M</given-names></name><name><surname>Peuralinna</surname><given-names>T</given-names></name><name><surname>Dutra</surname><given-names>A</given-names></name><name><surname>Nussbaum</surname><given-names>R</given-names></name><name><surname>Lincoln</surname><given-names>S</given-names></name><name><surname>Crawley</surname><given-names>A</given-names></name><name><surname>Hanson</surname><given-names>M</given-names></name><name><surname>Maraganore</surname><given-names>D</given-names></name><name><surname>Adler</surname><given-names>C</given-names></name><name><surname>Cookson</surname><given-names>MR</given-names></name><name><surname>Muenter</surname><given-names>M</given-names></name><name><surname>Baptista</surname><given-names>M</given-names></name><name><surname>Miller</surname><given-names>D</given-names></name><name><surname>Blancato</surname><given-names>J</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Gwinn-Hardy</surname><given-names>K</given-names></name><article-title>alpha-Synuclein locus triplication causes Parkinson&#x02019;s disease</article-title><source>Science</source><year>2003</year><volume>302</volume><fpage>841</fpage><pub-id pub-id-type="pmid">14593171</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Chartier-Harlin</surname><given-names>MC</given-names></name><name><surname>Kachergus</surname><given-names>J</given-names></name><name><surname>Roumier</surname><given-names>C</given-names></name><name><surname>Mouroux</surname><given-names>V</given-names></name><name><surname>Douay</surname><given-names>X</given-names></name><name><surname>Lincoln</surname><given-names>S</given-names></name><name><surname>Levecque</surname><given-names>C</given-names></name><name><surname>Larvor</surname><given-names>L</given-names></name><name><surname>Andrieux</surname><given-names>J</given-names></name><name><surname>Hulihan</surname><given-names>M</given-names></name><name><surname>Waucquier</surname><given-names>N</given-names></name><name><surname>Defebvre</surname><given-names>L</given-names></name><name><surname>Amouyel</surname><given-names>P</given-names></name><name><surname>Farrer</surname><given-names>M</given-names></name><name><surname>Destee</surname><given-names>A</given-names></name><article-title>Alpha-synuclein locus duplication as a cause of familial Parkinson&#x02019;s
disease</article-title><source>Lancet</source><year>2004</year><volume>364</volume><fpage>1167</fpage><lpage>1169</lpage><pub-id pub-id-type="pmid">15451224</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Ibanez</surname><given-names>P</given-names></name><name><surname>Bonnet</surname><given-names>AM</given-names></name><name><surname>Debarges</surname><given-names>B</given-names></name><name><surname>Lohmann</surname><given-names>E</given-names></name><name><surname>Tison</surname><given-names>F</given-names></name><name><surname>Pollak</surname><given-names>P</given-names></name><name><surname>Agid</surname><given-names>Y</given-names></name><name><surname>Durr</surname><given-names>A</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name><article-title>Causal relation between alpha-synuclein gene duplication and familial
Parkinson&#x02019;s disease</article-title><source>Lancet</source><year>2004</year><volume>364</volume><fpage>1169</fpage><lpage>1171</lpage><pub-id pub-id-type="pmid">15451225</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Fuchs</surname><given-names>J</given-names></name><name><surname>Nilsson</surname><given-names>C</given-names></name><name><surname>Kachergus</surname><given-names>J</given-names></name><name><surname>Munz</surname><given-names>M</given-names></name><name><surname>Larsson</surname><given-names>EM</given-names></name><name><surname>Schule</surname><given-names>B</given-names></name><name><surname>Langston</surname><given-names>JW</given-names></name><name><surname>Middleton</surname><given-names>FA</given-names></name><name><surname>Ross</surname><given-names>OA</given-names></name><name><surname>Hulihan</surname><given-names>M</given-names></name><name><surname>Gasser</surname><given-names>T</given-names></name><name><surname>Farrer</surname><given-names>MJ</given-names></name><article-title>Phenotypic variation in a large Swedish pedigree due to SNCA duplication and
triplication</article-title><source>Neurology</source><year>2007</year><volume>68</volume><fpage>916</fpage><lpage>922</lpage><pub-id pub-id-type="pmid">17251522</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Nishioka</surname><given-names>K</given-names></name><name><surname>Ross</surname><given-names>OA</given-names></name><name><surname>Ishii</surname><given-names>K</given-names></name><name><surname>Kachergus</surname><given-names>JM</given-names></name><name><surname>Ishiwata</surname><given-names>K</given-names></name><name><surname>Kitagawa</surname><given-names>M</given-names></name><name><surname>Kono</surname><given-names>S</given-names></name><name><surname>Obi</surname><given-names>T</given-names></name><name><surname>Mizoguchi</surname><given-names>K</given-names></name><name><surname>Inoue</surname><given-names>Y</given-names></name><name><surname>Imai</surname><given-names>H</given-names></name><name><surname>Takanashi</surname><given-names>M</given-names></name><name><surname>Mizuno</surname><given-names>Y</given-names></name><name><surname>Farrer</surname><given-names>MJ</given-names></name><name><surname>Hattori</surname><given-names>N</given-names></name><article-title>Expanding the clinical phenotype of SNCA duplication carriers</article-title><source>Mov Disord</source><year>2009</year><volume>24</volume><fpage>1811</fpage><lpage>1819</lpage><pub-id pub-id-type="pmid">19562770</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Murphy</surname><given-names>DD</given-names></name><name><surname>Rueter</surname><given-names>SM</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name><article-title>Synucleins are developmentally expressed, and alpha-synuclein regulates the size
of the presynaptic vesicular pool in primary hippocampal neurons</article-title><source>J Neurosci</source><year>2000</year><volume>20</volume><fpage>3214</fpage><lpage>3220</lpage><pub-id pub-id-type="pmid">10777786</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Bonini</surname><given-names>NM</given-names></name><name><surname>Giasson</surname><given-names>BI</given-names></name><article-title>Snaring the function of alpha-synuclein</article-title><source>Cell</source><year>2005</year><volume>123</volume><fpage>359</fpage><lpage>361</lpage><pub-id pub-id-type="pmid">16269324</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Burre</surname><given-names>J</given-names></name><name><surname>Sharma</surname><given-names>M</given-names></name><name><surname>Tsetsenis</surname><given-names>T</given-names></name><name><surname>Buchman</surname><given-names>V</given-names></name><name><surname>Etherton</surname><given-names>MR</given-names></name><name><surname>Sudhof</surname><given-names>TC</given-names></name><article-title>Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro</article-title><source>Science</source><year>2010</year><volume>329</volume><fpage>1663</fpage><lpage>1667</lpage><pub-id pub-id-type="pmid">20798282</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Kokhan</surname><given-names>VS</given-names></name><name><surname>Afanasyeva</surname><given-names>MA</given-names></name><name><surname>Van&#x02019;kin</surname><given-names>GI</given-names></name><article-title>alpha-Synuclein knockout mice have cognitive impairments</article-title><source>Behav Brain Res</source><year>2012</year><volume>231</volume><fpage>226</fpage><lpage>230</lpage><pub-id pub-id-type="pmid">22469626</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Okochi</surname><given-names>M</given-names></name><name><surname>Walter</surname><given-names>J</given-names></name><name><surname>Koyama</surname><given-names>A</given-names></name><name><surname>Nakajo</surname><given-names>S</given-names></name><name><surname>Baba</surname><given-names>M</given-names></name><name><surname>Iwatsubo</surname><given-names>T</given-names></name><name><surname>Meijer</surname><given-names>L</given-names></name><name><surname>Kahle</surname><given-names>PJ</given-names></name><name><surname>Haass</surname><given-names>C</given-names></name><article-title>Constitutive phosphorylation of the Parkinson&#x02019;s disease associated
alpha-synuclein</article-title><source>J Biol Chem</source><year>2000</year><volume>275</volume><fpage>390</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">10617630</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Yamashita</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>S</given-names></name><article-title>Activated Fyn phosphorylates alpha-synuclein at tyrosine residue 125</article-title><source>Biochem Biophys Res Commun</source><year>2001</year><volume>280</volume><fpage>1085</fpage><lpage>1092</lpage><pub-id pub-id-type="pmid">11162638</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Anderson</surname><given-names>JP</given-names></name><name><surname>Walker</surname><given-names>DE</given-names></name><name><surname>Goldstein</surname><given-names>JM</given-names></name><name><surname>de Laat</surname><given-names>R</given-names></name><name><surname>Banducci</surname><given-names>K</given-names></name><name><surname>Caccavello</surname><given-names>RJ</given-names></name><name><surname>Barbour</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Kling</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Diep</surname><given-names>L</given-names></name><name><surname>Keim</surname><given-names>PS</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name><name><surname>Chataway</surname><given-names>T</given-names></name><name><surname>Schlossmacher</surname><given-names>MG</given-names></name><name><surname>Seubert</surname><given-names>P</given-names></name><name><surname>Schenk</surname><given-names>D</given-names></name><name><surname>Sinha</surname><given-names>S</given-names></name><name><surname>Gai</surname><given-names>WP</given-names></name><name><surname>Chilcote</surname><given-names>TJ</given-names></name><article-title>Phosphorylation of Ser-129 is the dominant pathological modification of
alpha-synuclein in familial and sporadic Lewy body disease</article-title><source>J Biol Chem</source><year>2006</year><volume>281</volume><fpage>29739</fpage><lpage>29752</lpage><pub-id pub-id-type="pmid">16847063</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Nonaka</surname><given-names>T</given-names></name><name><surname>Iwatsubo</surname><given-names>T</given-names></name><name><surname>Hasegawa</surname><given-names>M</given-names></name><article-title>Ubiquitination of alpha-synuclein</article-title><source>Biochemistry</source><year>2005</year><volume>44</volume><fpage>361</fpage><lpage>368</lpage><pub-id pub-id-type="pmid">15628878</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>House</surname><given-names>CM</given-names></name><name><surname>Hancock</surname><given-names>NC</given-names></name><name><surname>Moller</surname><given-names>A</given-names></name><name><surname>Cromer</surname><given-names>BA</given-names></name><name><surname>Fedorov</surname><given-names>V</given-names></name><name><surname>Bowtell</surname><given-names>DD</given-names></name><name><surname>Parker</surname><given-names>MW</given-names></name><name><surname>Polekhina</surname><given-names>G</given-names></name><article-title>Elucidation of the substrate binding site of Siah ubiquitin ligase</article-title><source>Structure</source><year>2006</year><volume>14</volume><fpage>695</fpage><lpage>701</lpage><pub-id pub-id-type="pmid">16615911</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>JT</given-names></name><name><surname>Wheeler</surname><given-names>TC</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Chin</surname><given-names>LS</given-names></name><article-title>Ubiquitination of alpha-synuclein by Siah-1 promotes alpha-synuclein aggregation
and apoptotic cell death</article-title><source>Hum Mol Genet</source><year>2008</year><volume>17</volume><fpage>906</fpage><lpage>917</lpage><pub-id pub-id-type="pmid">18065497</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>Giasson</surname><given-names>BI</given-names></name><name><surname>Duda</surname><given-names>JE</given-names></name><name><surname>Murray</surname><given-names>IV</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Souza</surname><given-names>JM</given-names></name><name><surname>Hurtig</surname><given-names>HI</given-names></name><name><surname>Ischiropoulos</surname><given-names>H</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name><article-title>Oxidative damage linked to neurodegeneration by selective alpha-synuclein
nitration in synucleinopathy lesions</article-title><source>Science</source><year>2000</year><volume>290</volume><fpage>985</fpage><lpage>989</lpage><pub-id pub-id-type="pmid">11062131</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Qiang</surname><given-names>M</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>R</given-names></name><article-title>A novel molecular mechanism for nitrated &#x003b1;-synuclein-induced cell death</article-title><source>J Mol Cell Biol</source><year>2011</year><volume>3</volume><fpage>239</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">21733982</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><name><surname>Danielson</surname><given-names>SR</given-names></name><name><surname>Held</surname><given-names>JM</given-names></name><name><surname>Schilling</surname><given-names>B</given-names></name><name><surname>Oo</surname><given-names>M</given-names></name><name><surname>Gibson</surname><given-names>BW</given-names></name><name><surname>Andersen</surname><given-names>JK</given-names></name><article-title>Preferentially increased nitration of alpha-synuclein at tyrosine-39 in a cellular
oxidative model of Parkinson&#x02019;s disease</article-title><source>Anal Chem</source><year>2009</year><volume>81</volume><fpage>7823</fpage><lpage>7828</lpage><pub-id pub-id-type="pmid">19697948</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><name><surname>Kordower</surname><given-names>JH</given-names></name><name><surname>Chu</surname><given-names>Y</given-names></name><name><surname>Hauser</surname><given-names>RA</given-names></name><name><surname>Freeman</surname><given-names>TB</given-names></name><name><surname>Olanow</surname><given-names>CW</given-names></name><article-title>Lewy body-like pathology in long-term embryonic nigral transplants in
Parkinson&#x02019;s disease</article-title><source>Nat Med</source><year>2008</year><volume>14</volume><fpage>504</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">18391962</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>JY</given-names></name><name><surname>Englund</surname><given-names>E</given-names></name><name><surname>Holton</surname><given-names>JL</given-names></name><name><surname>Soulet</surname><given-names>D</given-names></name><name><surname>Hagell</surname><given-names>P</given-names></name><name><surname>Lees</surname><given-names>AJ</given-names></name><name><surname>Lashley</surname><given-names>T</given-names></name><name><surname>Quinn</surname><given-names>NP</given-names></name><name><surname>Rehncrona</surname><given-names>S</given-names></name><name><surname>Bjorklund</surname><given-names>A</given-names></name><name><surname>Widner</surname><given-names>H</given-names></name><name><surname>Revesz</surname><given-names>T</given-names></name><name><surname>Lindvall</surname><given-names>O</given-names></name><name><surname>Brundin</surname><given-names>P</given-names></name><article-title>Lewy bodies in grafted neurons in subjects with Parkinson&#x02019;s disease suggest
host-to-graft disease propagation</article-title><source>Nat Med</source><year>2008</year><volume>14</volume><fpage>501</fpage><lpage>503</lpage><pub-id pub-id-type="pmid">18391963</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><name><surname>Brundin</surname><given-names>P</given-names></name><name><surname>Melki</surname><given-names>R</given-names></name><name><surname>Kopito</surname><given-names>R</given-names></name><article-title>Prion-like transmission of protein aggregates in neurodegenerative diseases</article-title><source>Nat Rev Mol Cell Biol</source><year>2010</year><volume>11</volume><fpage>301</fpage><lpage>307</lpage><pub-id pub-id-type="pmid">20308987</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>Del Tredici</surname><given-names>K</given-names></name><name><surname>Rub</surname><given-names>U</given-names></name><name><surname>de Vos</surname><given-names>RA</given-names></name><name><surname>Jansen Steur</surname><given-names>EN</given-names></name><name><surname>Braak</surname><given-names>E</given-names></name><article-title>Staging of brain pathology related to sporadic Parkinson&#x02019;s disease</article-title><source>Neurobiol Aging</source><year>2003</year><volume>24</volume><fpage>197</fpage><lpage>211</lpage><pub-id pub-id-type="pmid">12498954</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>Rub</surname><given-names>U</given-names></name><name><surname>Gai</surname><given-names>WP</given-names></name><name><surname>Del Tredici</surname><given-names>K</given-names></name><article-title>Idiopathic Parkinson&#x02019;s disease: possible routes by which vulnerable neuronal
types may be subject to neuroinvasion by an unknown pathogen</article-title><source>J Neural Transm</source><year>2003</year><volume>110</volume><fpage>517</fpage><lpage>536</lpage><pub-id pub-id-type="pmid">12721813</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><name><surname>Hansen</surname><given-names>C</given-names></name><name><surname>Angot</surname><given-names>E</given-names></name><name><surname>Bergstrom</surname><given-names>AL</given-names></name><name><surname>Steiner</surname><given-names>JA</given-names></name><name><surname>Pieri</surname><given-names>L</given-names></name><name><surname>Paul</surname><given-names>G</given-names></name><name><surname>Outeiro</surname><given-names>TF</given-names></name><name><surname>Melki</surname><given-names>R</given-names></name><name><surname>Kallunki</surname><given-names>P</given-names></name><name><surname>Fog</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>JY</given-names></name><name><surname>Brundin</surname><given-names>P</given-names></name><article-title>alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons and
seeds aggregation in cultured human cells</article-title><source>J Clin Invest</source><year>2011</year><volume>121</volume><fpage>715</fpage><lpage>725</lpage><pub-id pub-id-type="pmid">21245577</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><name><surname>Ulusoy</surname><given-names>A</given-names></name><name><surname>Rusconi</surname><given-names>R</given-names></name><name><surname>Perez-Revuelta</surname><given-names>BI</given-names></name><name><surname>Musgrove</surname><given-names>RE</given-names></name><name><surname>Helwig</surname><given-names>M</given-names></name><name><surname>Winzen-Reichert</surname><given-names>B</given-names></name><name><surname>Di Monte</surname><given-names>DA</given-names></name><article-title>Caudo-rostral brain spreading of alpha-synuclein through vagal connections</article-title><source>EMBO Mol Med</source><year>2013</year><volume>5</volume><fpage>1051</fpage><lpage>1059</lpage><pub-id pub-id-type="pmid">23703938</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><name><surname>Rey</surname><given-names>NL</given-names></name><name><surname>Petit</surname><given-names>GH</given-names></name><name><surname>Bousset</surname><given-names>L</given-names></name><name><surname>Melki</surname><given-names>R</given-names></name><name><surname>Brundin</surname><given-names>P</given-names></name><article-title>Transfer of human alpha-synuclein from the olfactory bulb to interconnected brain
regions in mice</article-title><source>Acta Neuropathol</source><year>2013</year><volume>126</volume><fpage>555</fpage><lpage>573</lpage><pub-id pub-id-type="pmid">23925565</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><name><surname>Luk</surname><given-names>KC</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name><article-title>Modeling Lewy pathology propagation in Parkinson&#x02019;s disease</article-title><source>Parkinsonism Relat Disord</source><year>2014</year><volume>20</volume><fpage>S85</fpage><lpage>S87</lpage><pub-id pub-id-type="pmid">24262196</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><name><surname>Recasens</surname><given-names>A</given-names></name><name><surname>Dehay</surname><given-names>B</given-names></name><name><surname>Bove</surname><given-names>J</given-names></name><name><surname>Carballo-Carbajal</surname><given-names>I</given-names></name><name><surname>Dovero</surname><given-names>S</given-names></name><name><surname>Perez-Villalba</surname><given-names>A</given-names></name><name><surname>Fernagut</surname><given-names>PO</given-names></name><name><surname>Blesa</surname><given-names>J</given-names></name><name><surname>Parent</surname><given-names>A</given-names></name><name><surname>Perier</surname><given-names>C</given-names></name><name><surname>Farinas</surname><given-names>I</given-names></name><name><surname>Obeso</surname><given-names>JA</given-names></name><name><surname>Bezard</surname><given-names>E</given-names></name><name><surname>Vila</surname><given-names>M</given-names></name><article-title>Lewy body extracts from Parkinson disease brains trigger alpha-synuclein pathology
and neurodegeneration in mice and monkeys</article-title><source>Ann Neurol</source><year>2014</year><volume>75</volume><fpage>351</fpage><lpage>362</lpage><pub-id pub-id-type="pmid">24243558</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><name><surname>Masuda-Suzukake</surname><given-names>M</given-names></name><name><surname>Nonaka</surname><given-names>T</given-names></name><name><surname>Hosokawa</surname><given-names>M</given-names></name><name><surname>Oikawa</surname><given-names>T</given-names></name><name><surname>Arai</surname><given-names>T</given-names></name><name><surname>Akiyama</surname><given-names>H</given-names></name><name><surname>Mann</surname><given-names>DM</given-names></name><name><surname>Hasegawa</surname><given-names>M</given-names></name><article-title>Prion-like spreading of pathological alpha-synuclein in brain</article-title><source>Brain</source><year>2013</year><volume>136</volume><fpage>1128</fpage><lpage>1138</lpage><pub-id pub-id-type="pmid">23466394</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><name><surname>Kretzschmar</surname><given-names>H</given-names></name><name><surname>Tatzelt</surname><given-names>J</given-names></name><article-title>Prion disease: a tale of folds and strains</article-title><source>Brain Pathol</source><year>2013</year><volume>23</volume><fpage>321</fpage><lpage>332</lpage><pub-id pub-id-type="pmid">23587138</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><name><surname>Bousset</surname><given-names>L</given-names></name><name><surname>Pieri</surname><given-names>L</given-names></name><name><surname>Ruiz-Arlandis</surname><given-names>G</given-names></name><name><surname>Gath</surname><given-names>J</given-names></name><name><surname>Jensen</surname><given-names>PH</given-names></name><name><surname>Habenstein</surname><given-names>B</given-names></name><name><surname>Madiona</surname><given-names>K</given-names></name><name><surname>Olieric</surname><given-names>V</given-names></name><name><surname>Bockmann</surname><given-names>A</given-names></name><name><surname>Meier</surname><given-names>BH</given-names></name><name><surname>Melki</surname><given-names>R</given-names></name><article-title>Structural and functional characterization of two alpha-synuclein strains</article-title><source>Nat Commun</source><year>2013</year><volume>4</volume><fpage>2575</fpage><pub-id pub-id-type="pmid">24108358</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><name><surname>Guo</surname><given-names>JL</given-names></name><name><surname>Covell</surname><given-names>DJ</given-names></name><name><surname>Daniels</surname><given-names>JP</given-names></name><name><surname>Iba</surname><given-names>M</given-names></name><name><surname>Stieber</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Riddle</surname><given-names>DM</given-names></name><name><surname>Kwong</surname><given-names>LK</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name><article-title>Distinct alpha-synuclein strains differentially promote tau inclusions in
neurons</article-title><source>Cell</source><year>2013</year><volume>154</volume><fpage>103</fpage><lpage>117</lpage><pub-id pub-id-type="pmid">23827677</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><name><surname>Narkiewicz</surname><given-names>J</given-names></name><name><surname>Giachin</surname><given-names>G</given-names></name><name><surname>Legname</surname><given-names>G</given-names></name><article-title>In vitro aggregation assays for the characterization of alpha-synuclein prion-like
properties</article-title><source>Prion</source><year>2014</year><volume>8</volume><fpage>19</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">24552879</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><name><surname>Halliday</surname><given-names>GM</given-names></name><name><surname>Holton</surname><given-names>JL</given-names></name><name><surname>Revesz</surname><given-names>T</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><article-title>Neuropathology underlying clinical variability in patients with
synucleinopathies</article-title><source>Acta Neuropathol</source><year>2011</year><volume>122</volume><fpage>187</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">21720849</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><name><surname>Spillantini</surname><given-names>MG</given-names></name><name><surname>Crowther</surname><given-names>RA</given-names></name><name><surname>Jakes</surname><given-names>R</given-names></name><name><surname>Hasegawa</surname><given-names>M</given-names></name><name><surname>Goedert</surname><given-names>M</given-names></name><article-title>alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson&#x02019;s
disease and dementia with lewy bodies</article-title><source>Proc Natl Acad Sci U S A</source><year>1998</year><volume>95</volume><fpage>6469</fpage><lpage>6473</lpage><pub-id pub-id-type="pmid">9600990</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><name><surname>Leng</surname><given-names>Y</given-names></name><name><surname>Chase</surname><given-names>TN</given-names></name><name><surname>Bennett</surname><given-names>MC</given-names></name><article-title>Muscarinic receptor stimulation induces translocation of an alpha-synuclein
oligomer from plasma membrane to a light vesicle fraction in cytoplasm</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>28212</fpage><lpage>28218</lpage><pub-id pub-id-type="pmid">11337491</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><name><surname>Davidson</surname><given-names>WS</given-names></name><name><surname>Jonas</surname><given-names>A</given-names></name><name><surname>Clayton</surname><given-names>DF</given-names></name><name><surname>George</surname><given-names>JM</given-names></name><article-title>Stabilization of alpha-synuclein secondary structure upon binding to synthetic
membranes</article-title><source>J Biol Chem</source><year>1998</year><volume>273</volume><fpage>9443</fpage><lpage>9449</lpage><pub-id pub-id-type="pmid">9545270</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><name><surname>Segrest</surname><given-names>JP</given-names></name><name><surname>Jones</surname><given-names>MK</given-names></name><name><surname>De Loof</surname><given-names>H</given-names></name><name><surname>Brouillette</surname><given-names>CG</given-names></name><name><surname>Venkatachalapathi</surname><given-names>YV</given-names></name><name><surname>Anantharamaiah</surname><given-names>GM</given-names></name><article-title>The amphipathic helix in the exchangeable apolipoproteins: a review of secondary
structure and function</article-title><source>J Lipid Res</source><year>1992</year><volume>33</volume><fpage>141</fpage><lpage>166</lpage><pub-id pub-id-type="pmid">1569369</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><name><surname>Cole</surname><given-names>NB</given-names></name><name><surname>Murphy</surname><given-names>DD</given-names></name><name><surname>Grider</surname><given-names>T</given-names></name><name><surname>Rueter</surname><given-names>S</given-names></name><name><surname>Brasaemle</surname><given-names>D</given-names></name><name><surname>Nussbaum</surname><given-names>RL</given-names></name><article-title>Lipid droplet binding and oligomerization properties of the Parkinson&#x02019;s
disease protein alpha-synuclein</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>6344</fpage><lpage>6352</lpage><pub-id pub-id-type="pmid">11744721</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><name><surname>Fortin</surname><given-names>DL</given-names></name><name><surname>Troyer</surname><given-names>MD</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Kubo</surname><given-names>S</given-names></name><name><surname>Anthony</surname><given-names>MD</given-names></name><name><surname>Edwards</surname><given-names>RH</given-names></name><article-title>Lipid rafts mediate the synaptic localization of alpha-synuclein</article-title><source>J Neurosci</source><year>2004</year><volume>24</volume><fpage>6715</fpage><lpage>6723</lpage><pub-id pub-id-type="pmid">15282274</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><name><surname>Bartels</surname><given-names>T</given-names></name><name><surname>Choi</surname><given-names>JG</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name><article-title>alpha-Synuclein occurs physiologically as a helically folded tetramer that resists
aggregation</article-title><source>Nature</source><year>2011</year><volume>477</volume><fpage>107</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">21841800</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><name><surname>McKeith</surname><given-names>IG</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Lowe</surname><given-names>J</given-names></name><name><surname>Emre</surname><given-names>M</given-names></name><name><surname>O'Brien</surname><given-names>JT</given-names></name><name><surname>Feldman</surname><given-names>H</given-names></name><name><surname>Cummings</surname><given-names>J</given-names></name><name><surname>Duda</surname><given-names>JE</given-names></name><name><surname>Lippa</surname><given-names>C</given-names></name><name><surname>Perry</surname><given-names>EK</given-names></name><name><surname>Aarsland</surname><given-names>D</given-names></name><name><surname>Arai</surname><given-names>H</given-names></name><name><surname>Ballard</surname><given-names>CG</given-names></name><name><surname>Boeve</surname><given-names>B</given-names></name><name><surname>Burn</surname><given-names>DJ</given-names></name><name><surname>Costa</surname><given-names>D</given-names></name><name><surname>Del Ser</surname><given-names>T</given-names></name><name><surname>Dubois</surname><given-names>B</given-names></name><name><surname>Galasko</surname><given-names>D</given-names></name><name><surname>Gauthier</surname><given-names>S</given-names></name><name><surname>Goetz</surname><given-names>CG</given-names></name><name><surname>Gomez-Tortosa</surname><given-names>E</given-names></name><name><surname>Halliday</surname><given-names>G</given-names></name><name><surname>Hansen</surname><given-names>LA</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Iwatsubo</surname><given-names>T</given-names></name><name><surname>Kalaria</surname><given-names>RN</given-names></name><name><surname>Kaufer</surname><given-names>D</given-names></name><name><surname>Kenny</surname><given-names>RA</given-names></name><name><surname>Korczyn</surname><given-names>A</given-names></name><etal/><article-title>Diagnosis and management of dementia with Lewy bodies: third report of the DLB
Consortium</article-title><source>Neurology</source><year>2005</year><volume>65</volume><fpage>1863</fpage><lpage>1872</lpage><pub-id pub-id-type="pmid">16237129</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><name><surname>Weisman</surname><given-names>D</given-names></name><name><surname>Cho</surname><given-names>M</given-names></name><name><surname>Taylor</surname><given-names>C</given-names></name><name><surname>Adame</surname><given-names>A</given-names></name><name><surname>Thal</surname><given-names>LJ</given-names></name><name><surname>Hansen</surname><given-names>LA</given-names></name><article-title>In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body
distribution</article-title><source>Neurology</source><year>2007</year><volume>69</volume><fpage>356</fpage><lpage>359</lpage><pub-id pub-id-type="pmid">17646627</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><name><surname>Fujishiro</surname><given-names>H</given-names></name><name><surname>Ferman</surname><given-names>TJ</given-names></name><name><surname>Boeve</surname><given-names>BF</given-names></name><name><surname>Smith</surname><given-names>GE</given-names></name><name><surname>Graff-Radford</surname><given-names>NR</given-names></name><name><surname>Uitti</surname><given-names>RJ</given-names></name><name><surname>Wszolek</surname><given-names>ZK</given-names></name><name><surname>Knopman</surname><given-names>DS</given-names></name><name><surname>Petersen</surname><given-names>RC</given-names></name><name><surname>Parisi</surname><given-names>JE</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><article-title>Validation of the neuropathologic criteria of the third consortium for dementia
with Lewy bodies for prospectively diagnosed cases</article-title><source>J Neuropathol Exp Neurol</source><year>2008</year><volume>67</volume><fpage>649</fpage><lpage>656</lpage><pub-id pub-id-type="pmid">18596548</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><name><surname>Oinas</surname><given-names>M</given-names></name><name><surname>Polvikoski</surname><given-names>T</given-names></name><name><surname>Sulkava</surname><given-names>R</given-names></name><name><surname>Myllykangas</surname><given-names>L</given-names></name><name><surname>Juva</surname><given-names>K</given-names></name><name><surname>Notkola</surname><given-names>IL</given-names></name><name><surname>Rastas</surname><given-names>S</given-names></name><name><surname>Niinisto</surname><given-names>L</given-names></name><name><surname>Kalimo</surname><given-names>H</given-names></name><name><surname>Paetau</surname><given-names>A</given-names></name><article-title>Neuropathologic findings of dementia with lewy bodies (DLB) in a population-based
Vantaa 85+ study</article-title><source>J Alzheimers Dis</source><year>2009</year><volume>18</volume><fpage>677</fpage><lpage>689</lpage><pub-id pub-id-type="pmid">19625740</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><name><surname>Walker</surname><given-names>Z</given-names></name><name><surname>Jaros</surname><given-names>E</given-names></name><name><surname>Walker</surname><given-names>RW</given-names></name><name><surname>Lee</surname><given-names>L</given-names></name><name><surname>Costa</surname><given-names>DC</given-names></name><name><surname>Livingston</surname><given-names>G</given-names></name><name><surname>Ince</surname><given-names>PG</given-names></name><name><surname>Perry</surname><given-names>R</given-names></name><name><surname>McKeith</surname><given-names>I</given-names></name><name><surname>Katona</surname><given-names>CL</given-names></name><article-title>Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single
photon emission computed tomography imaging and autopsy</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2007</year><volume>78</volume><fpage>1176</fpage><lpage>1181</lpage><pub-id pub-id-type="pmid">17353255</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><name><surname>Nelson</surname><given-names>PT</given-names></name><name><surname>Jicha</surname><given-names>GA</given-names></name><name><surname>Kryscio</surname><given-names>RJ</given-names></name><name><surname>Abner</surname><given-names>EL</given-names></name><name><surname>Schmitt</surname><given-names>FA</given-names></name><name><surname>Cooper</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>LO</given-names></name><name><surname>Smith</surname><given-names>CD</given-names></name><name><surname>Markesbery</surname><given-names>WR</given-names></name><article-title>Low sensitivity in clinical diagnoses of dementia with Lewy bodies</article-title><source>J Neurol</source><year>2010</year><volume>257</volume><fpage>359</fpage><lpage>366</lpage><pub-id pub-id-type="pmid">19795154</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><name><surname>Ferman</surname><given-names>TJ</given-names></name><name><surname>Boeve</surname><given-names>BF</given-names></name><name><surname>Smith</surname><given-names>GE</given-names></name><name><surname>Lin</surname><given-names>SC</given-names></name><name><surname>Silber</surname><given-names>MH</given-names></name><name><surname>Pedraza</surname><given-names>O</given-names></name><name><surname>Wszolek</surname><given-names>Z</given-names></name><name><surname>Graff-Radford</surname><given-names>NR</given-names></name><name><surname>Uitti</surname><given-names>R</given-names></name><name><surname>Van Gerpen</surname><given-names>J</given-names></name><name><surname>Pao</surname><given-names>W</given-names></name><name><surname>Knopman</surname><given-names>D</given-names></name><name><surname>Pankratz</surname><given-names>VS</given-names></name><name><surname>Kantarci</surname><given-names>K</given-names></name><name><surname>Boot</surname><given-names>B</given-names></name><name><surname>Parisi</surname><given-names>JE</given-names></name><name><surname>Dugger</surname><given-names>BN</given-names></name><name><surname>Fujishiro</surname><given-names>H</given-names></name><name><surname>Petersen</surname><given-names>RC</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><article-title>Inclusion of RBD improves the diagnostic classification of dementia with Lewy
bodies</article-title><source>Neurology</source><year>2011</year><volume>77</volume><fpage>875</fpage><lpage>882</lpage><pub-id pub-id-type="pmid">21849645</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>Duda</surname><given-names>JE</given-names></name><name><surname>Duyckaerts</surname><given-names>C</given-names></name><name><surname>Gasser</surname><given-names>T</given-names></name><name><surname>Halliday</surname><given-names>GM</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Leverenz</surname><given-names>JB</given-names></name><name><surname>Del Tredici</surname><given-names>K</given-names></name><name><surname>Wszolek</surname><given-names>ZK</given-names></name><name><surname>Litvan</surname><given-names>I</given-names></name><article-title>Neuropathological assessment of Parkinson&#x02019;s disease: refining the diagnostic
criteria</article-title><source>Lancet Neurol</source><year>2009</year><volume>8</volume><fpage>1150</fpage><lpage>1157</lpage><pub-id pub-id-type="pmid">19909913</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><name><surname>Kovacs</surname><given-names>GG</given-names></name><name><surname>Alafuzoff</surname><given-names>I</given-names></name><name><surname>Al-Sarraj</surname><given-names>S</given-names></name><name><surname>Arzberger</surname><given-names>T</given-names></name><name><surname>Bogdanovic</surname><given-names>N</given-names></name><name><surname>Capellari</surname><given-names>S</given-names></name><name><surname>Ferrer</surname><given-names>I</given-names></name><name><surname>Gelpi</surname><given-names>E</given-names></name><name><surname>Kovari</surname><given-names>V</given-names></name><name><surname>Kretzschmar</surname><given-names>H</given-names></name><name><surname>Nagy</surname><given-names>Z</given-names></name><name><surname>Parchi</surname><given-names>P</given-names></name><name><surname>Seilhean</surname><given-names>D</given-names></name><name><surname>Soininen</surname><given-names>H</given-names></name><name><surname>Troakes</surname><given-names>C</given-names></name><name><surname>Budka</surname><given-names>H</given-names></name><article-title>Mixed brain pathologies in dementia: the BrainNet Europe consortium experience</article-title><source>Dement Geriatr Cogn Disord</source><year>2008</year><volume>26</volume><fpage>343</fpage><lpage>350</lpage><pub-id pub-id-type="pmid">18849605</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><name><surname>Ballard</surname><given-names>C</given-names></name><name><surname>Ziabreva</surname><given-names>I</given-names></name><name><surname>Perry</surname><given-names>R</given-names></name><name><surname>Larsen</surname><given-names>JP</given-names></name><name><surname>O'Brien</surname><given-names>J</given-names></name><name><surname>McKeith</surname><given-names>I</given-names></name><name><surname>Perry</surname><given-names>E</given-names></name><name><surname>Aarsland</surname><given-names>D</given-names></name><article-title>Differences in neuropathologic characteristics across the Lewy body dementia
spectrum</article-title><source>Neurology</source><year>2006</year><volume>67</volume><fpage>1931</fpage><lpage>1934</lpage><pub-id pub-id-type="pmid">17159096</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><name><surname>Tiraboschi</surname><given-names>P</given-names></name><name><surname>Hansen</surname><given-names>LA</given-names></name><name><surname>Alford</surname><given-names>M</given-names></name><name><surname>Sabbagh</surname><given-names>MN</given-names></name><name><surname>Schoos</surname><given-names>B</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Thal</surname><given-names>LJ</given-names></name><name><surname>Corey-Bloom</surname><given-names>J</given-names></name><article-title>Cholinergic dysfunction in diseases with Lewy bodies</article-title><source>Neurology</source><year>2000</year><volume>54</volume><fpage>407</fpage><lpage>411</lpage><pub-id pub-id-type="pmid">10668703</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><name><surname>Shimada</surname><given-names>H</given-names></name><name><surname>Hirano</surname><given-names>S</given-names></name><name><surname>Shinotoh</surname><given-names>H</given-names></name><name><surname>Aotsuka</surname><given-names>A</given-names></name><name><surname>Sato</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>N</given-names></name><name><surname>Ota</surname><given-names>T</given-names></name><name><surname>Asahina</surname><given-names>M</given-names></name><name><surname>Fukushi</surname><given-names>K</given-names></name><name><surname>Kuwabara</surname><given-names>S</given-names></name><name><surname>Hattori</surname><given-names>T</given-names></name><name><surname>Suhara</surname><given-names>T</given-names></name><name><surname>Irie</surname><given-names>T</given-names></name><article-title>Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET</article-title><source>Neurology</source><year>2009</year><volume>73</volume><fpage>273</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">19474411</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><name><surname>Marcone</surname><given-names>A</given-names></name><name><surname>Garibotto</surname><given-names>V</given-names></name><name><surname>Moresco</surname><given-names>RM</given-names></name><name><surname>Florea</surname><given-names>I</given-names></name><name><surname>Panzacchi</surname><given-names>A</given-names></name><name><surname>Carpinelli</surname><given-names>A</given-names></name><name><surname>Virta</surname><given-names>JR</given-names></name><name><surname>Tettamanti</surname><given-names>M</given-names></name><name><surname>Borroni</surname><given-names>B</given-names></name><name><surname>Padovani</surname><given-names>A</given-names></name><name><surname>Bertoldo</surname><given-names>A</given-names></name><name><surname>Herholz</surname><given-names>K</given-names></name><name><surname>Rinne</surname><given-names>JO</given-names></name><name><surname>Cappa</surname><given-names>SF</given-names></name><name><surname>Perani</surname><given-names>D</given-names></name><article-title>[11C]-MP4A PET cholinergic measurements in amnestic mild cognitive impairment,
probable Alzheimer&#x02019;s disease, and dementia with Lewy bodies: a Bayesian
method and voxel-based analysis</article-title><source>J Alzheimers Dis</source><year>2012</year><volume>31</volume><fpage>387</fpage><lpage>399</lpage><pub-id pub-id-type="pmid">22596267</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><name><surname>Laske</surname><given-names>C</given-names></name><name><surname>Fallgatter</surname><given-names>AJ</given-names></name><name><surname>Stransky</surname><given-names>E</given-names></name><name><surname>Hagen</surname><given-names>K</given-names></name><name><surname>Berg</surname><given-names>D</given-names></name><name><surname>Maetzler</surname><given-names>W</given-names></name><article-title>Decreased alpha-synuclein serum levels in patients with Lewy body dementia
compared to Alzheimer&#x02019;s disease patients and control subjects</article-title><source>Dement Geriatr Cogn Disord</source><year>2011</year><volume>31</volume><fpage>413</fpage><lpage>416</lpage><pub-id pub-id-type="pmid">21757905</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><name><surname>Gelb</surname><given-names>DJ</given-names></name><name><surname>Oliver</surname><given-names>E</given-names></name><name><surname>Gilman</surname><given-names>S</given-names></name><article-title>Diagnostic criteria for Parkinson disease</article-title><source>Arch Neurol</source><year>1999</year><volume>56</volume><fpage>33</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">9923759</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><name><surname>Emre</surname><given-names>M</given-names></name><name><surname>Aarsland</surname><given-names>D</given-names></name><name><surname>Brown</surname><given-names>R</given-names></name><name><surname>Burn</surname><given-names>DJ</given-names></name><name><surname>Duyckaerts</surname><given-names>C</given-names></name><name><surname>Mizuno</surname><given-names>Y</given-names></name><name><surname>Broe</surname><given-names>GA</given-names></name><name><surname>Cummings</surname><given-names>J</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Gauthier</surname><given-names>S</given-names></name><name><surname>Goldman</surname><given-names>J</given-names></name><name><surname>Goetz</surname><given-names>C</given-names></name><name><surname>Korczyn</surname><given-names>A</given-names></name><name><surname>Lees</surname><given-names>A</given-names></name><name><surname>Levy</surname><given-names>R</given-names></name><name><surname>Litvan</surname><given-names>I</given-names></name><name><surname>McKeith</surname><given-names>I</given-names></name><name><surname>Olanow</surname><given-names>W</given-names></name><name><surname>Poewe</surname><given-names>W</given-names></name><name><surname>Quinn</surname><given-names>N</given-names></name><name><surname>Sampaio</surname><given-names>C</given-names></name><name><surname>Tolosa</surname><given-names>E</given-names></name><name><surname>Dubois</surname><given-names>B</given-names></name><article-title>Clinical diagnostic criteria for dementia associated with Parkinson&#x02019;s
disease</article-title><source>Mov Disord</source><year>2007</year><volume>22</volume><fpage>1689</fpage><lpage>1707</lpage><pub-id pub-id-type="pmid">17542011</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><name><surname>Irwin</surname><given-names>DJ</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><article-title>Parkinson&#x02019;s disease dementia: convergence of alpha-synuclein, tau and
amyloid-beta pathologies</article-title><source>Nat Rev Neurosci</source><year>2013</year><volume>14</volume><fpage>626</fpage><lpage>636</lpage><pub-id pub-id-type="pmid">23900411</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Broe</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Anderson</surname><given-names>JP</given-names></name><name><surname>Gai</surname><given-names>WP</given-names></name><name><surname>Milward</surname><given-names>EA</given-names></name><name><surname>Porritt</surname><given-names>M</given-names></name><name><surname>Howells</surname><given-names>D</given-names></name><name><surname>Hughes</surname><given-names>AJ</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Halliday</surname><given-names>GM</given-names></name><article-title>Changes in the solubility and phosphorylation of alpha-synuclein over the course
of Parkinson&#x02019;s disease</article-title><source>Acta Neuropathol</source><year>2011</year><volume>121</volume><fpage>695</fpage><lpage>704</lpage><pub-id pub-id-type="pmid">21400129</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><name><surname>Lue</surname><given-names>LF</given-names></name><name><surname>Walker</surname><given-names>DG</given-names></name><name><surname>Adler</surname><given-names>CH</given-names></name><name><surname>Shill</surname><given-names>H</given-names></name><name><surname>Tran</surname><given-names>H</given-names></name><name><surname>Akiyama</surname><given-names>H</given-names></name><name><surname>Sue</surname><given-names>LI</given-names></name><name><surname>Caviness</surname><given-names>J</given-names></name><name><surname>Sabbagh</surname><given-names>MN</given-names></name><name><surname>Beach</surname><given-names>TG</given-names></name><article-title>Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of
Lewy-type synucleinopathies</article-title><source>Brain Pathol</source><year>2012</year><volume>22</volume><fpage>745</fpage><lpage>756</lpage><pub-id pub-id-type="pmid">22369130</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><name><surname>Walker</surname><given-names>DG</given-names></name><name><surname>Lue</surname><given-names>LF</given-names></name><name><surname>Adler</surname><given-names>CH</given-names></name><name><surname>Shill</surname><given-names>HA</given-names></name><name><surname>Caviness</surname><given-names>JN</given-names></name><name><surname>Sabbagh</surname><given-names>MN</given-names></name><name><surname>Akiyama</surname><given-names>H</given-names></name><name><surname>Serrano</surname><given-names>GE</given-names></name><name><surname>Sue</surname><given-names>LI</given-names></name><name><surname>Beach</surname><given-names>TG</given-names></name><article-title>Changes in properties of serine 129 phosphorylated alpha-synuclein with
progression of Lewy-type histopathology in human brains</article-title><source>Exp Neurol</source><year>2013</year><volume>240</volume><fpage>190</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">23201181</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><name><surname>Tong</surname><given-names>J</given-names></name><name><surname>Wong</surname><given-names>H</given-names></name><name><surname>Guttman</surname><given-names>M</given-names></name><name><surname>Ang</surname><given-names>LC</given-names></name><name><surname>Forno</surname><given-names>LS</given-names></name><name><surname>Shimadzu</surname><given-names>M</given-names></name><name><surname>Rajput</surname><given-names>AH</given-names></name><name><surname>Muenter</surname><given-names>MD</given-names></name><name><surname>Kish</surname><given-names>SJ</given-names></name><name><surname>Hornykiewicz</surname><given-names>O</given-names></name><name><surname>Furukawa</surname><given-names>Y</given-names></name><article-title>Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson&#x02019;s
disease and progressive supranuclear palsy: a comparative investigation</article-title><source>Brain</source><year>2010</year><volume>133</volume><fpage>172</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">19903734</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><name><surname>Halliday</surname><given-names>G</given-names></name><name><surname>Hely</surname><given-names>M</given-names></name><name><surname>Reid</surname><given-names>W</given-names></name><name><surname>Morris</surname><given-names>J</given-names></name><article-title>The progression of pathology in longitudinally followed patients with
Parkinson&#x02019;s disease</article-title><source>Acta Neuropathol</source><year>2008</year><volume>115</volume><fpage>409</fpage><lpage>415</lpage><pub-id pub-id-type="pmid">18231798</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><name><surname>Wenning</surname><given-names>G</given-names></name><name><surname>Tison</surname><given-names>F</given-names></name><name><surname>Ben Shlomo</surname><given-names>Y</given-names></name><name><surname>Daniel</surname><given-names>S</given-names></name><name><surname>Quinn</surname><given-names>N</given-names></name><article-title>Multiple system atrophy: a review of 203 pathologically proven cases</article-title><source>Mov Disord</source><year>1997</year><volume>12</volume><fpage>133</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">9087971</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><name><surname>Ozawa</surname><given-names>T</given-names></name><name><surname>Okuizumi</surname><given-names>K</given-names></name><name><surname>Ikeuchi</surname><given-names>T</given-names></name><name><surname>Wakabayashi</surname><given-names>K</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Tsuji</surname><given-names>S</given-names></name><article-title>Analysis of the expression level of alpha-synuclein mRNA using postmortem brain
samples from pathologically confirmed cases of multiple system atrophy</article-title><source>Acta Neuropathol</source><year>2001</year><volume>102</volume><fpage>188</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">11563635</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><name><surname>Baker</surname><given-names>KG</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>McCann</surname><given-names>H</given-names></name><name><surname>Gai</surname><given-names>WP</given-names></name><name><surname>Jensen</surname><given-names>PH</given-names></name><name><surname>Halliday</surname><given-names>GM</given-names></name><article-title>P25alpha immunoreactive but alpha-synuclein immunonegative neuronal inclusions in
multiple system atrophy</article-title><source>Acta Neuropathol</source><year>2006</year><volume>111</volume><fpage>193</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">16421739</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>YJ</given-names></name><name><surname>Murphy</surname><given-names>K</given-names></name><name><surname>Holton</surname><given-names>JL</given-names></name><name><surname>Lashley</surname><given-names>T</given-names></name><name><surname>Revesz</surname><given-names>T</given-names></name><name><surname>Gai</surname><given-names>WP</given-names></name><name><surname>Halliday</surname><given-names>GM</given-names></name><article-title>LRRK2 and parkin immunoreactivity in multiple system atrophy inclusions</article-title><source>Acta Neuropathol</source><year>2008</year><volume>116</volume><fpage>639</fpage><lpage>646</lpage><pub-id pub-id-type="pmid">18936941</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><name><surname>Song</surname><given-names>YJ</given-names></name><name><surname>Lundvig</surname><given-names>DM</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Gai</surname><given-names>WP</given-names></name><name><surname>Blumbergs</surname><given-names>PC</given-names></name><name><surname>Hojrup</surname><given-names>P</given-names></name><name><surname>Otzen</surname><given-names>D</given-names></name><name><surname>Halliday</surname><given-names>GM</given-names></name><name><surname>Jensen</surname><given-names>PH</given-names></name><article-title>p25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in
multiple system atrophy</article-title><source>Am J Pathol</source><year>2007</year><volume>171</volume><fpage>1291</fpage><lpage>1303</lpage><pub-id pub-id-type="pmid">17823288</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><name><surname>Jin</surname><given-names>H</given-names></name><name><surname>Ishikawa</surname><given-names>K</given-names></name><name><surname>Tsunemi</surname><given-names>T</given-names></name><name><surname>Ishiguro</surname><given-names>T</given-names></name><name><surname>Amino</surname><given-names>T</given-names></name><name><surname>Mizusawa</surname><given-names>H</given-names></name><article-title>Analyses of copy number and mRNA expression level of the alpha-synuclein gene in
multiple system atrophy</article-title><source>J Med Dental Sci</source><year>2008</year><volume>55</volume><fpage>145</fpage><lpage>153</lpage></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><name><surname>Morris</surname><given-names>HR</given-names></name><name><surname>Vaughan</surname><given-names>JR</given-names></name><name><surname>Datta</surname><given-names>SR</given-names></name><name><surname>Bandopadhyay</surname><given-names>R</given-names></name><name><surname>Rohan De Silva</surname><given-names>HA</given-names></name><name><surname>Schrag</surname><given-names>A</given-names></name><name><surname>Cairns</surname><given-names>NJ</given-names></name><name><surname>Burn</surname><given-names>D</given-names></name><name><surname>Nath</surname><given-names>U</given-names></name><name><surname>Lantos</surname><given-names>PL</given-names></name><name><surname>Daniel</surname><given-names>S</given-names></name><name><surname>Lees</surname><given-names>AJ</given-names></name><name><surname>Quinn</surname><given-names>NP</given-names></name><name><surname>Wood</surname><given-names>NW</given-names></name><article-title>Multiple system atrophy/progressive supranuclear palsy: alpha-synuclein,
synphilin, tau, and APOE</article-title><source>Neurology</source><year>2000</year><volume>55</volume><fpage>1918</fpage><lpage>1920</lpage><pub-id pub-id-type="pmid">11134398</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><name><surname>Ozawa</surname><given-names>T</given-names></name><name><surname>Takano</surname><given-names>H</given-names></name><name><surname>Onodera</surname><given-names>O</given-names></name><name><surname>Kobayashi</surname><given-names>H</given-names></name><name><surname>Ikeuchi</surname><given-names>T</given-names></name><name><surname>Koide</surname><given-names>R</given-names></name><name><surname>Okuizumi</surname><given-names>K</given-names></name><name><surname>Shimohata</surname><given-names>T</given-names></name><name><surname>Wakabayashi</surname><given-names>K</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Tsuji</surname><given-names>S</given-names></name><article-title>No mutation in the entire coding region of the alpha-synuclein gene in
pathologically confirmed cases of multiple system atrophy</article-title><source>Neurosci Lett</source><year>1999</year><volume>270</volume><fpage>110</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">10462110</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal"><name><surname>Al-Chalabi</surname><given-names>A</given-names></name><name><surname>Durr</surname><given-names>A</given-names></name><name><surname>Wood</surname><given-names>NW</given-names></name><name><surname>Parkinson</surname><given-names>MH</given-names></name><name><surname>Camuzat</surname><given-names>A</given-names></name><name><surname>Hulot</surname><given-names>JS</given-names></name><name><surname>Morrison</surname><given-names>KE</given-names></name><name><surname>Renton</surname><given-names>A</given-names></name><name><surname>Sussmuth</surname><given-names>SD</given-names></name><name><surname>Landwehrmeyer</surname><given-names>BG</given-names></name><name><surname>Ludolph</surname><given-names>A</given-names></name><name><surname>Agid</surname><given-names>Y</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name><name><surname>Leigh</surname><given-names>PN</given-names></name><name><surname>Bensimon</surname><given-names>G</given-names></name><article-title>Genetic variants of the alpha-synuclein gene SNCA are associated with multiple
system atrophy</article-title><source>PLoS One</source><year>2009</year><volume>4</volume><fpage>e7114</fpage><pub-id pub-id-type="pmid">19771175</pub-id></mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal"><name><surname>Scholz</surname><given-names>SW</given-names></name><name><surname>Houlden</surname><given-names>H</given-names></name><name><surname>Schulte</surname><given-names>C</given-names></name><name><surname>Sharma</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>A</given-names></name><name><surname>Berg</surname><given-names>D</given-names></name><name><surname>Melchers</surname><given-names>A</given-names></name><name><surname>Paudel</surname><given-names>R</given-names></name><name><surname>Gibbs</surname><given-names>JR</given-names></name><name><surname>Simon-Sanchez</surname><given-names>J</given-names></name><name><surname>Paisan-Ruiz</surname><given-names>C</given-names></name><name><surname>Bras</surname><given-names>J</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Traynor</surname><given-names>BJ</given-names></name><name><surname>Arepalli</surname><given-names>S</given-names></name><name><surname>Zonozi</surname><given-names>RR</given-names></name><name><surname>Revesz</surname><given-names>T</given-names></name><name><surname>Holton</surname><given-names>J</given-names></name><name><surname>Wood</surname><given-names>N</given-names></name><name><surname>Lees</surname><given-names>A</given-names></name><name><surname>Oertel</surname><given-names>W</given-names></name><name><surname>Wullner</surname><given-names>U</given-names></name><name><surname>Goldwurm</surname><given-names>S</given-names></name><name><surname>Pellecchia</surname><given-names>MT</given-names></name><name><surname>Illig</surname><given-names>T</given-names></name><name><surname>Riess</surname><given-names>O</given-names></name><name><surname>Fernandez</surname><given-names>HH</given-names></name><name><surname>Rodriguez</surname><given-names>RL</given-names></name><name><surname>Okun</surname><given-names>M</given-names></name><etal/><article-title>SNCA variants are associated with increased risk for multiple system atrophy</article-title><source>Ann Neurol</source><year>2009</year><volume>65</volume><fpage>610</fpage><lpage>614</lpage><pub-id pub-id-type="pmid">19475667</pub-id></mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal"><name><surname>Stemberger</surname><given-names>S</given-names></name><name><surname>Scholz</surname><given-names>SW</given-names></name><name><surname>Singleton</surname><given-names>AB</given-names></name><name><surname>Wenning</surname><given-names>GK</given-names></name><article-title>Genetic players in multiple system atrophy: unfolding the nature of the beast</article-title><source>Neurobiol Aging</source><year>1924</year><volume>2011</volume><fpage>e5</fpage><lpage>e14</lpage></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="journal"><name><surname>Sailer</surname><given-names>A</given-names></name><article-title>First genome-wide association study in multiple system atrophy</article-title><source>Mov Disord</source><year>2012</year><volume>27</volume><fpage>1425</fpage><pub-id pub-id-type="pmid">22886735</pub-id></mixed-citation></ref><ref id="B96"><mixed-citation publication-type="journal"><name><surname>Stefanova</surname><given-names>N</given-names></name><name><surname>Reindl</surname><given-names>M</given-names></name><name><surname>Neumann</surname><given-names>M</given-names></name><name><surname>Haass</surname><given-names>C</given-names></name><name><surname>Poewe</surname><given-names>W</given-names></name><name><surname>Kahle</surname><given-names>PJ</given-names></name><name><surname>Wenning</surname><given-names>GK</given-names></name><article-title>Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein
overexpression replicates the characteristic neuropathology of multiple system
atrophy</article-title><source>Am J Pathol</source><year>2005</year><volume>166</volume><fpage>869</fpage><lpage>876</lpage><pub-id pub-id-type="pmid">15743798</pub-id></mixed-citation></ref><ref id="B97"><mixed-citation publication-type="journal"><name><surname>Miller</surname><given-names>DW</given-names></name><name><surname>Johnson</surname><given-names>JM</given-names></name><name><surname>Solano</surname><given-names>SM</given-names></name><name><surname>Hollingsworth</surname><given-names>ZR</given-names></name><name><surname>Standaert</surname><given-names>DG</given-names></name><name><surname>Young</surname><given-names>AB</given-names></name><article-title>Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy
oligodendroglia</article-title><source>J Neural Transm</source><year>2005</year><volume>112</volume><fpage>1613</fpage><lpage>1624</lpage><pub-id pub-id-type="pmid">16284907</pub-id></mixed-citation></ref><ref id="B98"><mixed-citation publication-type="journal"><name><surname>Mori</surname><given-names>F</given-names></name><name><surname>Tanji</surname><given-names>K</given-names></name><name><surname>Yoshimoto</surname><given-names>M</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Wakabayashi</surname><given-names>K</given-names></name><article-title>Demonstration of alpha-synuclein immunoreactivity in neuronal and glial cytoplasm
in normal human brain tissue using proteinase K and formic acid pretreatment</article-title><source>Exp Neurol</source><year>2002</year><volume>176</volume><fpage>98</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">12093086</pub-id></mixed-citation></ref><ref id="B99"><mixed-citation publication-type="journal"><name><surname>Richter-Landsberg</surname><given-names>C</given-names></name><name><surname>Gorath</surname><given-names>M</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name><article-title>alpha-synuclein is developmentally expressed in cultured rat brain
oligodendrocytes</article-title><source>J Neurosci Res</source><year>2000</year><volume>62</volume><fpage>9</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">11002283</pub-id></mixed-citation></ref><ref id="B100"><mixed-citation publication-type="journal"><name><surname>Kahle</surname><given-names>PJ</given-names></name><name><surname>Neumann</surname><given-names>M</given-names></name><name><surname>Ozmen</surname><given-names>L</given-names></name><name><surname>Muller</surname><given-names>V</given-names></name><name><surname>Jacobsen</surname><given-names>H</given-names></name><name><surname>Spooren</surname><given-names>W</given-names></name><name><surname>Fuss</surname><given-names>B</given-names></name><name><surname>Mallon</surname><given-names>B</given-names></name><name><surname>Macklin</surname><given-names>WB</given-names></name><name><surname>Fujiwara</surname><given-names>H</given-names></name><name><surname>Hasegawa</surname><given-names>M</given-names></name><name><surname>Iwatsubo</surname><given-names>T</given-names></name><name><surname>Kretzschmar</surname><given-names>HA</given-names></name><name><surname>Haass</surname><given-names>C</given-names></name><article-title>Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse
oligodendrocytes</article-title><source>EMBO Rep</source><year>2002</year><volume>3</volume><fpage>583</fpage><lpage>588</lpage><pub-id pub-id-type="pmid">12034752</pub-id></mixed-citation></ref><ref id="B101"><mixed-citation publication-type="journal"><name><surname>Yazawa</surname><given-names>I</given-names></name><name><surname>Giasson</surname><given-names>BI</given-names></name><name><surname>Sasaki</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Joyce</surname><given-names>S</given-names></name><name><surname>Uryu</surname><given-names>K</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name><article-title>Mouse model of multiple system atrophy alpha-synuclein expression in
oligodendrocytes causes glial and neuronal degeneration</article-title><source>Neuron</source><year>2005</year><volume>45</volume><fpage>847</fpage><lpage>859</lpage><pub-id pub-id-type="pmid">15797547</pub-id></mixed-citation></ref><ref id="B102"><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>HJ</given-names></name><name><surname>Suk</surname><given-names>JE</given-names></name><name><surname>Bae</surname><given-names>EJ</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name><article-title>Clearance and deposition of extracellular alpha-synuclein aggregates in
microglia</article-title><source>Biochem Biophys Res Commun</source><year>2008</year><volume>372</volume><fpage>423</fpage><lpage>428</lpage><pub-id pub-id-type="pmid">18492487</pub-id></mixed-citation></ref><ref id="B103"><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>HJ</given-names></name><name><surname>Suk</surname><given-names>JE</given-names></name><name><surname>Patrick</surname><given-names>C</given-names></name><name><surname>Bae</surname><given-names>EJ</given-names></name><name><surname>Cho</surname><given-names>JH</given-names></name><name><surname>Rho</surname><given-names>S</given-names></name><name><surname>Hwang</surname><given-names>D</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name><article-title>Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory
responses in synucleinopathies</article-title><source>J Biol Chem</source><year>2010</year><volume>285</volume><fpage>9262</fpage><lpage>9272</lpage><pub-id pub-id-type="pmid">20071342</pub-id></mixed-citation></ref><ref id="B104"><mixed-citation publication-type="journal"><name><surname>Toledo</surname><given-names>JB</given-names></name><name><surname>Cairns</surname><given-names>NJ</given-names></name><name><surname>Da</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Carter</surname><given-names>D</given-names></name><name><surname>Fleisher</surname><given-names>A</given-names></name><name><surname>Householder</surname><given-names>E</given-names></name><name><surname>Ayutyanont</surname><given-names>N</given-names></name><name><surname>Roontiva</surname><given-names>A</given-names></name><name><surname>Bauer</surname><given-names>RJ</given-names></name><name><surname>Eisen</surname><given-names>P</given-names></name><name><surname>Shaw</surname><given-names>LM</given-names></name><name><surname>Davatzikos</surname><given-names>C</given-names></name><name><surname>Weiner</surname><given-names>MW</given-names></name><name><surname>Reiman</surname><given-names>EM</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><article-title>Clinical and multimodal biomarker correlates of ADNI neuropathological
findings</article-title><source>Acta Neuropathol Commun</source><year>2013</year><volume>1</volume><fpage>65</fpage><pub-id pub-id-type="pmid">24252435</pub-id></mixed-citation></ref><ref id="B105"><mixed-citation publication-type="journal"><name><surname>Mikolaenko</surname><given-names>I</given-names></name><name><surname>Pletnikova</surname><given-names>O</given-names></name><name><surname>Kawas</surname><given-names>CH</given-names></name><name><surname>O'Brien</surname><given-names>R</given-names></name><name><surname>Resnick</surname><given-names>SM</given-names></name><name><surname>Crain</surname><given-names>B</given-names></name><name><surname>Troncoso</surname><given-names>JC</given-names></name><article-title>Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease:
evidence from the Baltimore Longitudinal Study of Aging (BLSA)</article-title><source>J Neuropathol Exp Neurol</source><year>2005</year><volume>64</volume><fpage>156</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">15751230</pub-id></mixed-citation></ref><ref id="B106"><mixed-citation publication-type="journal"><name><surname>Hamilton</surname><given-names>RL</given-names></name><article-title>Lewy bodies in Alzheimer&#x02019;s disease: a neuropathological review of 145 cases
using alpha-synuclein immunohistochemistry</article-title><source>Brain Pathol</source><year>2000</year><volume>10</volume><fpage>378</fpage><lpage>384</lpage><pub-id pub-id-type="pmid">10885656</pub-id></mixed-citation></ref><ref id="B107"><mixed-citation publication-type="journal"><name><surname>Iseki</surname><given-names>E</given-names></name><article-title>Dementia with Lewy bodies: reclassification of pathological subtypes and boundary
with Parkinson&#x02019;s disease or Alzheimer&#x02019;s disease</article-title><source>Neuropathology</source><year>2004</year><volume>24</volume><fpage>72</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">15068176</pub-id></mixed-citation></ref><ref id="B108"><mixed-citation publication-type="journal"><name><surname>Marui</surname><given-names>W</given-names></name><name><surname>Iseki</surname><given-names>E</given-names></name><name><surname>Ueda</surname><given-names>K</given-names></name><name><surname>Kosaka</surname><given-names>K</given-names></name><article-title>Occurrence of human alpha-synuclein immunoreactive neurons with neurofibrillary
tangle formation in the limbic areas of patients with Alzheimer&#x02019;s
disease</article-title><source>J Neurol Sci</source><year>2000</year><volume>174</volume><fpage>81</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">10727692</pub-id></mixed-citation></ref><ref id="B109"><mixed-citation publication-type="journal"><name><surname>Compta</surname><given-names>Y</given-names></name><name><surname>Parkkinen</surname><given-names>L</given-names></name><name><surname>O'Sullivan</surname><given-names>SS</given-names></name><name><surname>Vandrovcova</surname><given-names>J</given-names></name><name><surname>Holton</surname><given-names>JL</given-names></name><name><surname>Collins</surname><given-names>C</given-names></name><name><surname>Lashley</surname><given-names>T</given-names></name><name><surname>Kallis</surname><given-names>C</given-names></name><name><surname>Williams</surname><given-names>DR</given-names></name><name><surname>de Silva</surname><given-names>R</given-names></name><name><surname>Lees</surname><given-names>AJ</given-names></name><name><surname>Revesz</surname><given-names>T</given-names></name><article-title>Lewy- and Alzheimer-type pathologies in Parkinson&#x02019;s disease dementia: which
is more important?</article-title><source>Brain</source><year>2011</year><volume>134</volume><fpage>1493</fpage><lpage>1505</lpage><pub-id pub-id-type="pmid">21596773</pub-id></mixed-citation></ref><ref id="B110"><mixed-citation publication-type="journal"><name><surname>Kovari</surname><given-names>E</given-names></name><name><surname>Gold</surname><given-names>G</given-names></name><name><surname>Herrmann</surname><given-names>FR</given-names></name><name><surname>Canuto</surname><given-names>A</given-names></name><name><surname>Hof</surname><given-names>PR</given-names></name><name><surname>Bouras</surname><given-names>C</given-names></name><name><surname>Giannakopoulos</surname><given-names>P</given-names></name><article-title>Lewy body densities in the entorhinal and anterior cingulate cortex predict
cognitive deficits in Parkinson&#x02019;s disease</article-title><source>Acta Neuropathol</source><year>2003</year><volume>106</volume><fpage>83</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">12687392</pub-id></mixed-citation></ref><ref id="B111"><mixed-citation publication-type="journal"><name><surname>Jellinger</surname><given-names>KA</given-names></name><name><surname>Seppi</surname><given-names>K</given-names></name><name><surname>Wenning</surname><given-names>GK</given-names></name><name><surname>Poewe</surname><given-names>W</given-names></name><article-title>Impact of coexistent Alzheimer pathology on the natural history of
Parkinson&#x02019;s disease</article-title><source>J Neural Transm</source><year>2002</year><volume>109</volume><fpage>329</fpage><lpage>339</lpage><pub-id pub-id-type="pmid">11956955</pub-id></mixed-citation></ref><ref id="B112"><mixed-citation publication-type="journal"><name><surname>Irwin</surname><given-names>DJ</given-names></name><name><surname>White</surname><given-names>MT</given-names></name><name><surname>Toledo</surname><given-names>JB</given-names></name><name><surname>Xie</surname><given-names>SX</given-names></name><name><surname>Robinson</surname><given-names>JL</given-names></name><name><surname>Van Deerlin</surname><given-names>V</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name><name><surname>Leverenz</surname><given-names>JB</given-names></name><name><surname>Montine</surname><given-names>TJ</given-names></name><name><surname>Duda</surname><given-names>JE</given-names></name><name><surname>Hurtig</surname><given-names>HI</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><article-title>Neuropathologic substrates of Parkinson disease dementia</article-title><source>Ann Neurol</source><year>2012</year><volume>72</volume><fpage>587</fpage><lpage>598</lpage><pub-id pub-id-type="pmid">23037886</pub-id></mixed-citation></ref><ref id="B113"><mixed-citation publication-type="journal"><name><surname>Clinton</surname><given-names>LK</given-names></name><name><surname>Blurton-Jones</surname><given-names>M</given-names></name><name><surname>Myczek</surname><given-names>K</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>LaFerla</surname><given-names>FM</given-names></name><article-title>Synergistic interactions between Abeta, tau, and alpha-synuclein: acceleration of
neuropathology and cognitive decline</article-title><source>J Neurosci</source><year>2010</year><volume>30</volume><fpage>7281</fpage><lpage>7289</lpage><pub-id pub-id-type="pmid">20505094</pub-id></mixed-citation></ref><ref id="B114"><mixed-citation publication-type="journal"><name><surname>Giasson</surname><given-names>BI</given-names></name><name><surname>Duda</surname><given-names>JE</given-names></name><name><surname>Quinn</surname><given-names>SM</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name><article-title>Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing
A53T human alpha-synuclein</article-title><source>Neuron</source><year>2002</year><volume>34</volume><fpage>521</fpage><lpage>533</lpage><pub-id pub-id-type="pmid">12062037</pub-id></mixed-citation></ref><ref id="B115"><mixed-citation publication-type="journal"><name><surname>Rolinski</surname><given-names>M</given-names></name><name><surname>Fox</surname><given-names>C</given-names></name><name><surname>Maidment</surname><given-names>I</given-names></name><name><surname>McShane</surname><given-names>R</given-names></name><article-title>Cholinesterase inhibitors for dementia with Lewy bodies. Parkinson&#x02019;s disease
dementia and cognitive impairment in Parkinson&#x02019;s disease</article-title><source>Cochrane Database Syst Rev</source><year>2012</year><volume>3</volume><fpage>CD006504</fpage><pub-id pub-id-type="pmid">22419314</pub-id></mixed-citation></ref><ref id="B116"><mixed-citation publication-type="journal"><name><surname>Ballard</surname><given-names>CG</given-names></name><name><surname>Chalmers</surname><given-names>KA</given-names></name><name><surname>Todd</surname><given-names>C</given-names></name><name><surname>McKeith</surname><given-names>IG</given-names></name><name><surname>O'Brien</surname><given-names>JT</given-names></name><name><surname>Wilcock</surname><given-names>G</given-names></name><name><surname>Love</surname><given-names>S</given-names></name><name><surname>Perry</surname><given-names>EK</given-names></name><article-title>Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies</article-title><source>Neurology</source><year>2007</year><volume>68</volume><fpage>1726</fpage><lpage>1729</lpage><pub-id pub-id-type="pmid">17502555</pub-id></mixed-citation></ref><ref id="B117"><mixed-citation publication-type="journal"><name><surname>Vekrellis</surname><given-names>K</given-names></name><name><surname>Stefanis</surname><given-names>L</given-names></name><article-title>Targeting intracellular and extracellular alpha-synuclein as a therapeutic
strategy in Parkinson&#x02019;s disease and other synucleinopathies</article-title><source>Expert Opin Ther Targets</source><year>2012</year><volume>16</volume><fpage>421</fpage><lpage>432</lpage><pub-id pub-id-type="pmid">22480256</pub-id></mixed-citation></ref><ref id="B118"><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>HJ</given-names></name><name><surname>Bae</surname><given-names>EJ</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name><article-title>Extracellular alpha-synuclein &#x02013; a novel and crucial factor in Lewy body
diseases</article-title><source>Nat Rev Neurol</source><year>2014</year><volume>10</volume><fpage>92</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">24468877</pub-id></mixed-citation></ref><ref id="B119"><mixed-citation publication-type="journal"><name><surname>Marchiani</surname><given-names>A</given-names></name><name><surname>Mammi</surname><given-names>S</given-names></name><name><surname>Siligardi</surname><given-names>G</given-names></name><name><surname>Hussain</surname><given-names>R</given-names></name><name><surname>Tessari</surname><given-names>I</given-names></name><name><surname>Bubacco</surname><given-names>L</given-names></name><name><surname>Delogu</surname><given-names>G</given-names></name><name><surname>Fabbri</surname><given-names>D</given-names></name><name><surname>Dettori</surname><given-names>MA</given-names></name><name><surname>Sanna</surname><given-names>D</given-names></name><name><surname>Dedola</surname><given-names>S</given-names></name><name><surname>Serra</surname><given-names>PA</given-names></name><name><surname>Ruzza</surname><given-names>P</given-names></name><article-title>Small molecules interacting with alpha-synuclein: antiaggregating and
cytoprotective properties</article-title><source>Amino Acids</source><year>2013</year><volume>45</volume><fpage>327</fpage><lpage>338</lpage><pub-id pub-id-type="pmid">23645386</pub-id></mixed-citation></ref><ref id="B120"><mixed-citation publication-type="journal"><name><surname>Moloney</surname><given-names>TC</given-names></name><name><surname>Hyland</surname><given-names>R</given-names></name><name><surname>O'Toole</surname><given-names>D</given-names></name><name><surname>Paucard</surname><given-names>A</given-names></name><name><surname>Kirik</surname><given-names>D</given-names></name><name><surname>O'Doherty</surname><given-names>A</given-names></name><name><surname>Gorman</surname><given-names>AM</given-names></name><name><surname>Dowd</surname><given-names>E</given-names></name><article-title>Heat shock protein 70 reduces alpha-synuclein-induced predegenerative neuronal
dystrophy in the alpha-synuclein viral gene transfer rat model of Parkinson's
disease</article-title><source>CNS Neurosci Ther</source><year>2014</year><volume>20</volume><fpage>50</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">24279716</pub-id></mixed-citation></ref><ref id="B121"><mixed-citation publication-type="journal"><name><surname>Putcha</surname><given-names>P</given-names></name><name><surname>Danzer</surname><given-names>KM</given-names></name><name><surname>Kranich</surname><given-names>LR</given-names></name><name><surname>Scott</surname><given-names>A</given-names></name><name><surname>Silinski</surname><given-names>M</given-names></name><name><surname>Mabbett</surname><given-names>S</given-names></name><name><surname>Hicks</surname><given-names>CD</given-names></name><name><surname>Veal</surname><given-names>JM</given-names></name><name><surname>Steed</surname><given-names>PM</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><name><surname>McLean</surname><given-names>PJ</given-names></name><article-title>Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein
oligomer formation and rescue alpha-synuclein-induced toxicity</article-title><source>J Pharmacol Exp Ther</source><year>2010</year><volume>332</volume><fpage>849</fpage><lpage>857</lpage><pub-id pub-id-type="pmid">19934398</pub-id></mixed-citation></ref><ref id="B122"><mixed-citation publication-type="journal"><name><surname>Toth</surname><given-names>G</given-names></name><name><surname>Gardai</surname><given-names>SJ</given-names></name><name><surname>Zago</surname><given-names>W</given-names></name><name><surname>Bertoncini</surname><given-names>CW</given-names></name><name><surname>Cremades</surname><given-names>N</given-names></name><name><surname>Roy</surname><given-names>SL</given-names></name><name><surname>Tambe</surname><given-names>MA</given-names></name><name><surname>Rochet</surname><given-names>JC</given-names></name><name><surname>Galvagnion</surname><given-names>C</given-names></name><name><surname>Skibinski</surname><given-names>G</given-names></name><name><surname>Finkbeiner</surname><given-names>S</given-names></name><name><surname>Bova</surname><given-names>M</given-names></name><name><surname>Regnstrom</surname><given-names>K</given-names></name><name><surname>Chiou</surname><given-names>SS</given-names></name><name><surname>Johnston</surname><given-names>J</given-names></name><name><surname>Callaway</surname><given-names>K</given-names></name><name><surname>Anderson</surname><given-names>JP</given-names></name><name><surname>Jobling</surname><given-names>MF</given-names></name><name><surname>Buell</surname><given-names>AK</given-names></name><name><surname>Yednock</surname><given-names>TA</given-names></name><name><surname>Knowles</surname><given-names>TP</given-names></name><name><surname>Vendruscolo</surname><given-names>M</given-names></name><name><surname>Christodoulou</surname><given-names>J</given-names></name><name><surname>Dobson</surname><given-names>CM</given-names></name><name><surname>Schenk</surname><given-names>D</given-names></name><name><surname>McConlogue</surname><given-names>L</given-names></name><article-title>Targeting the intrinsically disordered structural ensemble of alpha-synuclein by
small molecules as a potential therapeutic strategy for Parkinson&#x02019;s
disease</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><fpage>e87133</fpage><pub-id pub-id-type="pmid">24551051</pub-id></mixed-citation></ref><ref id="B123"><mixed-citation publication-type="journal"><name><surname>Jones</surname><given-names>DR</given-names></name><name><surname>Moussaud</surname><given-names>S</given-names></name><name><surname>McLean</surname><given-names>P</given-names></name><article-title>Targeting heat shock proteins to modulate alpha-synuclein toxicity</article-title><source>Ther Adv Neurol Disord</source><year>2014</year><volume>7</volume><fpage>33</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">24409201</pub-id></mixed-citation></ref><ref id="B124"><mixed-citation publication-type="journal"><name><surname>Sinha</surname><given-names>G</given-names></name><article-title>Roche bets on alpha-synuclein for Parkinson&#x02019;s</article-title><source>Nat Biotechnol</source><year>2014</year><volume>32</volume><fpage>212</fpage><pub-id pub-id-type="pmid">24727766</pub-id></mixed-citation></ref><ref id="B125"><mixed-citation publication-type="journal"><name><surname>Valera</surname><given-names>E</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><article-title>Immunotherapy for neurodegenerative diseases: focus on alpha-synucleinopathies</article-title><source>Pharmacol Ther</source><year>2013</year><volume>138</volume><fpage>311</fpage><lpage>322</lpage><pub-id pub-id-type="pmid">23384597</pub-id></mixed-citation></ref><ref id="B126"><mixed-citation publication-type="journal"><name><surname>Mandler</surname><given-names>M</given-names></name><name><surname>Valera</surname><given-names>E</given-names></name><name><surname>Rockenstein</surname><given-names>E</given-names></name><name><surname>Weninger</surname><given-names>H</given-names></name><name><surname>Patrick</surname><given-names>C</given-names></name><name><surname>Adame</surname><given-names>A</given-names></name><name><surname>Santic</surname><given-names>R</given-names></name><name><surname>Meindl</surname><given-names>S</given-names></name><name><surname>Vigl</surname><given-names>B</given-names></name><name><surname>Smrzka</surname><given-names>O</given-names></name><name><surname>Schneeberger</surname><given-names>A</given-names></name><name><surname>Mattner</surname><given-names>F</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><article-title>Next-generation active immunization approach for synucleinopathies: implications
for Parkinson&#x02019;s disease clinical trials</article-title><source>Acta Neuropathol</source><year>2014</year><volume>127</volume><fpage>861</fpage><lpage>879</lpage><pub-id pub-id-type="pmid">24525765</pub-id></mixed-citation></ref><ref id="B127"><mixed-citation publication-type="journal"><name><surname>Lindstrom</surname><given-names>V</given-names></name><name><surname>Ihse</surname><given-names>E</given-names></name><name><surname>Fagerqvist</surname><given-names>T</given-names></name><name><surname>Bergstrom</surname><given-names>J</given-names></name><name><surname>Nordstrom</surname><given-names>E</given-names></name><name><surname>Moller</surname><given-names>C</given-names></name><name><surname>Lannfelt</surname><given-names>L</given-names></name><name><surname>Ingelsson</surname><given-names>M</given-names></name><article-title>Immunotherapy targeting alpha-synuclein, with relevance for future treatment of
Parkinson&#x02019;s disease and other Lewy body disorders</article-title><source>Immunotherapy</source><year>2014</year><volume>6</volume><fpage>141</fpage><lpage>153</lpage><pub-id pub-id-type="pmid">24491088</pub-id></mixed-citation></ref><ref id="B128"><mixed-citation publication-type="journal"><name><surname>Ruzza</surname><given-names>P</given-names></name><name><surname>Siligardi</surname><given-names>G</given-names></name><name><surname>Hussain</surname><given-names>R</given-names></name><name><surname>Marchiani</surname><given-names>A</given-names></name><name><surname>Islami</surname><given-names>M</given-names></name><name><surname>Bubacco</surname><given-names>L</given-names></name><name><surname>Delogu</surname><given-names>G</given-names></name><name><surname>Fabbri</surname><given-names>D</given-names></name><name><surname>Dettori</surname><given-names>MA</given-names></name><name><surname>Sechi</surname><given-names>M</given-names></name><name><surname>Pala</surname><given-names>N</given-names></name><name><surname>Spissu</surname><given-names>Y</given-names></name><name><surname>Migheli</surname><given-names>R</given-names></name><name><surname>Serra</surname><given-names>PA</given-names></name><name><surname>Sechi</surname><given-names>G</given-names></name><article-title>Ceftriaxone blocks the polymerization of alpha-synuclein and exerts
neuroprotective effects in vitro</article-title><source>ACS Chem Neurosci</source><year>2014</year><volume>5</volume><fpage>30</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">24099687</pub-id></mixed-citation></ref><ref id="B129"><mixed-citation publication-type="journal"><name><surname>Low</surname><given-names>PA</given-names></name><name><surname>Robertson</surname><given-names>D</given-names></name><name><surname>Gilman</surname><given-names>S</given-names></name><name><surname>Kaufmann</surname><given-names>H</given-names></name><name><surname>Singer</surname><given-names>W</given-names></name><name><surname>Biaggioni</surname><given-names>I</given-names></name><name><surname>Freeman</surname><given-names>R</given-names></name><name><surname>Perlman</surname><given-names>S</given-names></name><name><surname>Hauser</surname><given-names>RA</given-names></name><name><surname>Cheshire</surname><given-names>W</given-names></name><name><surname>Lessig</surname><given-names>S</given-names></name><name><surname>Vernino</surname><given-names>S</given-names></name><name><surname>Mandrekar</surname><given-names>J</given-names></name><name><surname>Dupont</surname><given-names>WD</given-names></name><name><surname>Chelimsky</surname><given-names>T</given-names></name><name><surname>Galpern</surname><given-names>WR</given-names></name><article-title>Efficacy and safety of rifampicin for multiple system atrophy: a randomised,
double-blind, placebo-controlled trial</article-title><source>Lancet Neurol</source><year>2014</year><volume>13</volume><fpage>268</fpage><lpage>275</lpage><pub-id pub-id-type="pmid">24507091</pub-id></mixed-citation></ref></ref-list></back></article>